COOPERATIVE PATENT CLASSIFICATION

C CHEMISTRY; METALLURGY

CHEMISTRY

C12 BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLGY; MUTATION OR GENETIC ENGINEERING

C12N MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q 1/00)

NOTES

1. Documents relating to the use of vectors or hosts for the preparation of specific peptides, e.g. enzymes, are classified in subclass C07K or in group C12N 9/00 according to the peptides, with the appropriate indexing codes.

2. Attention is drawn to Notes (1) to (3) following the title of Class C12.

3. When classifying in this group, classification is also made in group B01D 15/08 insofar as subject matter of general interest relating to chromatography is concerned.

WARNINGS

1. The following IPC groups are not in the CPC scheme. The subject matter for these IPC groups is classified in the following CPC groups:

<table>
<thead>
<tr>
<th>IPC Group</th>
<th>Covered by</th>
</tr>
</thead>
<tbody>
<tr>
<td>C12N 1/11</td>
<td>C12N 15/79</td>
</tr>
<tr>
<td>C12N 1/13</td>
<td>C12N 15/79</td>
</tr>
<tr>
<td>C12N 1/15</td>
<td>C12N 15/80</td>
</tr>
<tr>
<td>C12N 1/19</td>
<td>C12N 15/81</td>
</tr>
<tr>
<td>C12N 1/21</td>
<td>C12N 15/74</td>
</tr>
<tr>
<td>C12N 5/02</td>
<td>C12N 5/0006, C12N 5/04 - C12N 5/166</td>
</tr>
<tr>
<td>C12N 5/07 - C12N 5/095</td>
<td>C12N 5/06</td>
</tr>
<tr>
<td>C12N 5/18</td>
<td>C12N 5/16</td>
</tr>
<tr>
<td>C12N 5/20</td>
<td>C12N 5/163</td>
</tr>
<tr>
<td>C12N 5/22</td>
<td>C12N 5/16</td>
</tr>
<tr>
<td>C12N 5/24</td>
<td>C12N 5/163</td>
</tr>
<tr>
<td>C12N 5/26</td>
<td>C12N 5/166</td>
</tr>
<tr>
<td>C12N 5/28</td>
<td>C12N 5/166</td>
</tr>
<tr>
<td>C12N 15/53</td>
<td>C12N 9/0004</td>
</tr>
<tr>
<td>C12N 7/01</td>
<td>C12N 7/00</td>
</tr>
<tr>
<td>C12N 9/02 - C12N 9/08</td>
<td>C12N 9/0004</td>
</tr>
<tr>
<td>C12N 9/26</td>
<td>C12N 9/2408</td>
</tr>
<tr>
<td>C12N 9/32</td>
<td>C12N 9/2422</td>
</tr>
<tr>
<td>C12N 9/34</td>
<td>C12N 9/2428</td>
</tr>
<tr>
<td>C12N 9/36</td>
<td>C12N 9/2462</td>
</tr>
<tr>
<td>C12N 9/38</td>
<td>C12N 9/2468</td>
</tr>
<tr>
<td>C12N 9/40</td>
<td>C12N 9/2465</td>
</tr>
<tr>
<td>C12N 9/42</td>
<td>C12N 9/2434</td>
</tr>
<tr>
<td>C12N 9/44</td>
<td>C12N 9/2451</td>
</tr>
<tr>
<td>C12N 9/46</td>
<td>C12N 9/2454</td>
</tr>
<tr>
<td>C12N 9/56</td>
<td>C12N 9/54</td>
</tr>
<tr>
<td>C12N 9/66</td>
<td>C12N 9/6448</td>
</tr>
<tr>
<td>C12N 9/68</td>
<td>C12N 9/6435</td>
</tr>
<tr>
<td>C12N 9/70</td>
<td>C07K 14/3153</td>
</tr>
<tr>
<td>C12N 9/72</td>
<td>C12N 9/6462</td>
</tr>
<tr>
<td>C12N 9/74</td>
<td>C12N 9/6429</td>
</tr>
<tr>
<td>C12N 9/76</td>
<td>C12N 9/6427</td>
</tr>
<tr>
<td>C12N 15/05</td>
<td>C12N 5/14</td>
</tr>
<tr>
<td>C12N 15/06</td>
<td>C12N 5/16</td>
</tr>
<tr>
<td>C12N 15/07</td>
<td>C12N 5/16</td>
</tr>
<tr>
<td>C12N 15/08</td>
<td>C12N 5/166</td>
</tr>
<tr>
<td>C12N 15/12</td>
<td>C07K 14/435</td>
</tr>
</tbody>
</table>
2. In this subclass non-limiting references (in the sense of paragraph 39 of the Guide to the IPC) may still be displayed in the scheme.
NOTE

A01H 4/00

(plant reproduction by tissue culture techniques)

A01N 1/02

(preservation of living cells or tissues)

A01K 67/027

(production of embryos, nuclear transfer)

A01K 67/027

(whole embryos; culture medium therefor)

A01H 4/00

(plant reproduction by tissue culture techniques)

NOTE

A01N 1/02

(preservation of living cells or tissues)

NOTE

A01K 67/027

(production of embryos, nuclear transfer)
5/0609 . . . [Oocytes, oogonia (fertilised oocytes C12N 5/0604)]
5/061 . . . [Sperm cells, spermatogonia]
5/0611 . . . [Primordial germ cells, e.g. embryonic germ cells [EGI]]
5/0612 . . . [sorting of gametes, e.g. according to sex or motility]
5/0613 . . . [Cells from endocrine organs (pancreas C12N 5/0676, gonads C12N 5/0681)]
5/0614 . . . [Adrenal gland]
5/0615 . . . [Pineal gland]
5/0616 . . . [Pituitary gland]
5/0617 . . . [Thyroid and parathyroid glands]
5/0618 . . . [Cells of the nervous system]
5/0619 . . . [Neurons]
5/062 . . . [Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain]
5/0621 . . . [Eye cells, e.g. cornea, iris pigmented cells (photoreceptors C12N 5/062)]
5/0622 . . . [Gial cells, e.g. astrocytes, oligodendrocytes; Schwann cells]
5/0623 . . . [Stem cells]
5/0625 . . . [Epidermal cells, skin cells; Cells of the oral mucosa]
5/0626 . . . [Melanocytes]
5/0627 . . . [Hair cells]
5/0628 . . . [Hair stem cells; Hair progenitors (mesenchymal stem cells from hair follicles C12N 5/0666)]
5/0629 . . . [Keratinocytes; Whole skin]
5/063 . . . [Keratinocyte stem cells; Keratinocyte progenitors]
5/0631 . . . [Mammary cells]
5/0632 . . . [Cells of the oral mucosa]
5/0633 . . . [Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrimal glands]
5/0634 . . . [Cells from the blood or the immune system]

**NOTE**
Committed progenitors are classified with their progeny

5/0635 . . . [B lymphocytes]
5/0636 . . . [T lymphocytes]
5/0637 . . . [Immunosuppressive T lymphocytes, e.g. regulatory T cells (Treg)]
5/0638 . . . [Cytotoxic T lymphocytes [CTL], lymphokine activated killer cells [LAK]]
5/0639 . . . [Dendritic cells, e.g. Langherhans cells in the epidermis]
5/064 . . . [Immunosuppressive dendritic cells]
5/0641 . . . [Erythrocytes]
5/0642 . . . [Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells]
5/0643 . . . [Osteoclasts]
5/0644 . . . [Platelets; Megakaryocytes]
5/0645 . . . [Macrophages, e.g. Kuepfer cells in the liver; Monocytes]
5/0646 . . . [Natural killers cells [NK], NKT cells]
5/0647 . . . [Haematopoietic stem cells; Uncommitted or multipotent progenitors]
5/0648 . . . [Splenocytes]
5/0649 . . . [Thymocytes]
5/065 . . . [Lymph nodes]
5/0651 . . . [Cells of skeletal and connective tissues; Mesenchyme]
5/0653 . . . [Adipocytes; Adipose tissue]
5/0654 . . . [Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth]
5/0655 . . . [Chondrocytes; Cartilage]
5/0656 . . . [Adult fibroblasts]
5/0657 . . . [Cardiomyocytes; Heart cells]
5/0658 . . . [Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts]
5/0659 . . . [Satellite cells]
5/066 . . . [Tenocytes; Tendons, Ligaments]
5/0661 . . . [Smooth muscle cells]
5/0662 . . . [Stem cells]
5/0663 . . . [Bone marrow mesenchymal stem cells (BM-MSC)]
5/0664 . . . [Dental pulp stem cells, Dental follicle stem cells]
5/0665 . . . [Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood]
5/0666 . . . [Mesenchymal stem cells from hair follicles]
5/0667 . . . [Adipose-derived stem cells [ADSC]; Adipose stromal stem cells]
5/0668 . . . [Mesenchymal stem cells from other natural sources]
5/0669 . . . [Bone marrow stromal cells; Whole bone marrow (isolated stem cells from bone marrow C12N 5/0647, C12N 5/0663)]
5/067 . . . [Hepatocytes]
5/0671 . . . [Three-dimensional culture, tissue culture or organ culture; Encapsulated cells]
5/0672 . . . [Stem cells; Progenitor cells; Precursor cells; Oval cells]
5/0676 . . . [Pancreatic cells]
5/0677 . . . [Three-dimensional culture, tissue culture or organ culture; Encapsulated cells]
5/0678 . . . [Stem cells; Progenitor cells; Precursor cells]
5/0679 . . . [Cells of the gastro-intestinal tract]
5/068 . . . [Stem cells; Progenitors]
5/0681 . . . [Cells of the genital tract; Non-germinal cells from gonads; Not used, see subgroups]
5/0682 . . . [Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes C12N 5/0609)]
5/0683 . . . [Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells (spermatogonia C12N 5/061)]
5/0684 . . . [Cells of the urinary tract or kidneys]
5/0685 . . . [Bladder epithelial cells]
5/0686 . . . [Kidney cells]
5/0687 . . . [Renal stem cells; Renal progenitors]
5/0688 . . . [Cells from the lungs or the respiratory tract]
5/0689 . . . [Stem cells; Progenitors]
5/069 . . . [Vascular Endothelial cells]
5/0691 . . . [Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels]
NOTE

Enzymes are generally categorized below according to the “Nomenclature and Classification of Enzymes” of the International Commission on Enzymes. Where appropriate, this designation appears in the groups below in parenthesis.

9/0002 . [Antibodies with enzymatic activity, e.g. abzymes]
9/0004 . [Oxidoreductases (1.1)]
9/0006 . [acting on CH-OH groups as donors (1.1)]
9/0008 . [acting on the aldehyde or oxo group of donors (1.2)]
9/0009 . [acting on the CH-CH group of donors (1.3)]
9/0012 . [acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)]
9/0014 . [acting on the CH-NH group of donors (1.4)]
9/0016 . [with NAD or NADP as acceptor (1.4.1)]
9/0018 . [Phenylalanine dehydrogenase (1.4.1.20)]
9/002 . [acting on a cytochrome as acceptor (1.4.2)]
9/0022 . [with oxygen as acceptor (1.4.3)]
9/0024 . [D-Amino acid oxidase (1.4.3.3)]
9/0026 . [acting on CH-NH groups of donors (1.5)]
9/0028 . [with NAD or NADP as acceptor (1.5.1)]
9/003 . [of Dihydrofolate reductase [DHFR] (1.5.1.3)]
9/0032 . [with oxygen as acceptor (1.5.3)]
9/0034 . [Sarcosine oxidase (1.5.3.1)]
9/0036 . [acting on NADH or NADPH (1.6.1)]
9/0038 . [with a heme protein as acceptor (1.6.2)]
9/004 . [Cytochrome-b5 reductase (1.6.2.2)]
9/0042 . [NADPH-cytochrome P450 reductase (1.6.2.4)]
9/0044 . [acting on other nitrogen compounds as donors (1.7)]
9/0046 . [with oxygen as acceptor (1.7.3)]
9/0048 . [Uricase (1.7.3.3)]
9/0051 . [acting on a sulfur group of donors (1.8)]
9/0053 . [acting on a heme group of donors (1.9)]
9/0055 . [acting on diphenols and related substances as donors (1.10)]
9/0057 . [with oxygen as acceptor (1.10.3)]
9/0059 . [Catechol oxidase (1.10.3.1), i.e. tyrosinase]
9/0061 . [Laccase (1.10.3.2)]
9/0063 . [Ascorbate oxidase (1.10.3.3)]
9/0065 . [acting on hydrogen peroxide as acceptor (1.11)]
9/0067 . [acting on hydrogen as donor (1.12)]
9/0069 . [acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)]
9/0071 . [acting on paired donors with incorporation of molecular oxygen (1.14)]
9/0073 . [with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13]
9/0077 . [with a reduced iron-sulfur protein as one donor (1.14.15)]
9/0079 . [Steroid 11 beta monoxygenase (P-450 protein) (1.14.15.4)]
9/0081 . [Cholesterol monoxygenase (cytochrome P 450ssc) (1.14.15.6)]
9/0083 . [Miscellaneous (1.14.99)]
9/0085 . [Steroid 17 alpha monoxygenase (1.14.99.93)]
9/0087 . [Steroid 21 monoxygenase (1.14.99.10)]
9/0089 . [acting on superoxide as acceptor (1.15)]
9/0091 . [oxidizing metal ions (1.16)]
9/0093 . [acting on CH or CH₂ groups (1.17)]
9/0095 . [acting on iron-sulfur proteins as donor (1.18)]
9/0097 . [acting on reduced flavodoxin as donor (1.19)]
9/10 . Transferases (2.) [ribonucleases C12N 9/22]
9/1003 . [transferring one-carbon groups (2.1)]
9/1007 . [Methyltransferases (general) (2.1.1.1)]
9/1011  . . . [Catechol-O-methyltransferase (2.1.1.6)]
9/1014  . . . [Hydroxymethyl-, formyl-transferases (2.1.2)]
9/1018  . . . [Carboxy- and carbamoyl transferases (2.1.3)]
9/1022  . . . [transferring aldehyde or ketonic groups (2.2)]
9/1025  . . . [Acyltransferases (2.3)]
9/1029  . . . [transferring groups other than amino-acyl groups (2.3.1)]
9/1033  . . . [Chloramphenicol O-acetyltransferase (2.3.1.28)]
9/1037  . . . [Naringenin-chalcone synthase (2.3.1.74), i.e. chalcone synthase]
9/104  . . . [Aminocarboxylic acid transferases (2.3.2)]
9/1044  . . . [Protein-glutamine gamma-gluanyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII]
9/1048  . . . [Glycosyltransferases (2.4)]
9/1051  . . . [Hexosyltransferases (2.4.1)]
9/1055  . . . [Levansucrase (2.4.1.10)]
9/1059  . . . [Cellulose synthases (2.4.1.12; 2.4.1.29)]
9/1062  . . . [Sucrose synthase (2.4.1.13)]
9/1066  . . . [Sucrose phosphate synthase (2.4.1.14)]
9/107  . . . [1.4-Alpha-glucan branching enzyme (2.4.1.18)]
9/1074  . . . [Cyclomaltodextrin glucanotransferase (2.4.1.19)]
9/1077  . . . [Pentosyltransferases (2.4.2)]
9/1081  . . . [transferring other glycosyl groups (2.4.99)]
9/1085  . . . [transferring aldehyde or ketonic groups other than methyl groups (2.5)]
9/1088  . . . [Glutathione transferase (2.5.1.18)]
9/1092  . . . [3-Phosphoglycerate 1-carboxyvinyltransferase (2.5.1.19), i.e. 5-enolpyruvylshikimate-3-phosphate synthase]
9/1096  . . . [transferring nitrogenous groups (2.6.1)]
9/12  . . . [transferring phosphorus containing groups, e.g. kinases (2.7)]
9/1205  . . . [Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases]
9/1211  . . . [Thymidine kinase (2.7.1.21)]
9/1217  . . . [Phosphotransferases with a carboxyl group as acceptor (2.7.2)]
9/1223  . . . [Phosphotransferases with a nitrogenous group as acceptor (2.7.3)]
9/1229  . . . [Phosphotransferases with a phosphate group as acceptor (2.7.4)]
9/1235  . . . [Diphosphotransferases (2.7.6)]
9/1241  . . . [Nucleotidylyltransferases (2.7.7)]
9/1247  . . . [DNA-directed RNA polymerase (2.7.7.6)]
9/1252  . . . [DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase]
9/1258  . . . [Polyribonucleotide nucleotidylyltransferase (2.7.7.8), i.e. polynucleotide phosphorylase]
9/1264  . . . [DNA nucelotidylyltransferase (2.7.7.31), i.e. terminal nucleotidylyl transferase]
9/127  . . . [RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase]
9/1276  . . . [RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase]
9/1282  . . . [RNA uridylyltransferase (2.7.7.52)]
9/1288  . . . [Transfers for other substituted phosphate groups (2.7.8)]
9/1294  . . . [Phosphotransferases with paired acceptors (2.7.9)]
9/13  . . . [transferring sulfur containing groups (2.8)]
9/14  . . . [Hydrolases (3)]
9/16  . . . [acting on ester bonds (3.1)]
9/18  . . . [Carboxylic ester hydrolases ([3.1.1)]
9/20  . . . [Triglyceride splitting, e.g. by means of lipase]
9/22  . . . [Ribonucleases {RNAse, DNase (catalytic nucleic acids C12N 15/113)}]
9/24  . . . [acting on glycosyl compounds (3.2)]
9/2402  . . . [hydrolysing O- and S-glycosyl compounds (3.2.1)]
9/2405  . . . [Glucanases]
9/2408  . . . [acting on alpha-1,4-glucosidic bonds]
9/2411  . . . [Amylases]
9/2414  . . . [Alpha-amylose (3.2.1.1)]
9/2417  . . . . . . { from microbial source]
9/242  . . . . . . { Fungal source]
9/2422  . . . . . . { from plant source]
9/2425  . . . . . . { Beta-amylose (3.2.1.2)}
9/2428  . . . . . . { Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucamylase]
9/2431  . . . . . . { Beta-fructofuranosidase (3.2.1.26), i.e. invertase]
9/2434  . . . . . . { acting on beta-1,4-glucosidic bonds]
9/2437  . . . . . . { Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)]
9/244  . . . . . . { Endo-1,3(4)-beta-glucanase (3.2.1.6)]
9/2442  . . . . . . { Chitinase (3.2.1.14)]
9/2445  . . . . . . { Beta-glucosidase (3.2.1.21)]
9/2448  . . . . . . { Licheninase (3.2.1.73)]
9/2451  . . . . . . { acting on alpha-1,6-glucosidic bonds]
9/2454  . . . . . . { Dextranase (3.2.1.11)]
9/2457  . . . . . . { Pullulanase (3.2.1.41)]
9/246  . . . . . . { Isoamylase (3.2.1.68)]
9/2462  . . . . . . { Lysozyme (3.2.1.17)]
9/2465  . . . . . . { acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.23)]
9/2468  . . . . . . { acting on beta-galacto-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); betaagarase (3.2.1.81)]
9/2471  . . . . . . { Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase]
9/2474  . . . . . . { Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase]
9/2477  . . . . . . { Hemicellulases not provided in a preceding group]
9/248  . . . . . . { Xylanases]
9/2482  . . . . . . { Endo-1,4-beta-xylanase (3.2.1.8)]
9/2485  . . . . . . { Xylan endo-1,3-beta-xilosidase (3.2.1.32), i.e. endo-1,3-beta-xylanase]
9/2488  . . . . . . { Mannanases]
9/2491  . . . . . . { Beta-mannosidase (3.2.1.25), i.e. mannanase]
9/2494  . . . . . . { Mannan endo-1,4-beta-mannosidase (3.2.1.32), i.e. endo-beta-mannanase]
9/2497  . . . . . . { hydrolysing N-glycosyl compounds (3.2.2)]
9/48  . . . . . . { acting on peptide bonds (3.4)]
9/485  . . . . . . { Exopeptidases (3.4.11-3.4.19)]
9/50 . . . . . . Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)

**WARNING**

Group C12N 9/50 is impacted by reclassification into group C12N 9/52. Groups C12N 9/50 and C12N 9/52 should be considered in order to perform a complete search.

9/503 . . . . (derived from viruses)
9/506 . . . . . . (derived from RNA viruses)
9/52 . . . . . . derived from bacteria [or Archaea]

**NOTE:**

{In this group, Archaea, formerly known as Archaebacteria, are classified with bacteria.}

**WARNING**

Group C12N 9/52 is incomplete pending reclassification of documents from group C12N 9/50. Groups C12N 9/50 and C12N 9/52 should be considered in order to perform a complete search.

9/54 . . . . . . bacteria being Bacillus
9/58 . . . . . . derived from fungi
9/60 . . . . . . from yeast
9/62 . . . . . . from Aspergillus
9/63 . . . . . . (derived from plants)
9/64 . . . . . . from animal tissue
9/6402 . . . . . . (from non-mammals)
9/6405 . . . . . . {not being snakes}
9/6408 . . . . . . [Serine endopeptidases (3.4.21)]
9/641 . . . . . . [Cysteine endopeptidases (3.4.22)]
9/6413 . . . . . . [Aspartic endopeptidases (3.4.23)]
9/6416 . . . . . . [Metalloendopeptidases (3.4.24)]
9/6418 . . . . . . {from snakes}
9/6421 . . . . . . {from mammals}
9/6424 . . . . . . [Serine endopeptidases (3.4.21)]
9/6427 . . . . . . [Thrombin (3.4.21.1); Trypsin (3.4.1.14)]
9/6429 . . . . . . [Thrombin (3.4.21.5)]
9/6432 . . . . . . [Coagulation factor Xa (3.4.21.6)]
9/6435 . . . . . . [Plasmin (3.4.21.7), i.e. fibrinolysin]
9/6437 . . . . . . [Coagulation factor VIIa (3.4.21.21)]
9/644 . . . . . . [Coagulation factor IXa (3.4.21.22)]
9/6443 . . . . . . [Coagulation factor XIa (3.4.21.27)]
9/6445 . . . . . . [Kallikreins (3.4.21.34; 3.4.21.35)]
9/6448 . . . . . . [Elastases, e.g. pancreatic elastase (3.4.21.36); leukocyte elastase (3.4.31.37)]
9/6451 . . . . . . [Coagulation factor XIIa (3.4.21.38)]
9/6454 . . . . . . [Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases]
9/6456 . . . . . . [Plasminogen activators]
9/6459 . . . . . . [t-Plasminogen activator (3.4.21.68), i.e. tPA]
9/6462 . . . . . . [u-Plasminogen activator (3.4.21.73); i.e. urokinase]

9/6464 . . . . . . [Protein C (3.4.21.69)]
9/6467 . . . . . . [Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)]
9/647 . . . . . . [Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups]
9/6472 . . . . . . [Cysteine endopeptidases (3.4.22)]
9/6475 . . . . . . [Interleukin-1 beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)]
9/6478 . . . . . . [Aspartic endopeptidases (3.4.23)]
9/6481 . . . . . . [Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)]
9/6483 . . . . . . [Chymosin (3.4.23.4), i.e. rennin]
9/6486 . . . . . . [Renin (3.4.23.15)]
9/6489 . . . . . . [Metalloendopeptidases (3.4.24)]
9/6491 . . . . . . [Matrix metalloproteinases [MMPs], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)]
9/6494 . . . . . . [Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11]
9/6497 . . . . . . [Endothelin-converting enzyme (3.4.24.71)]
9/78 . . . . . . acting on carbon to nitrogen bonds other than peptide bonds (3.5)
9/80 . . . . . . acting on amide bonds in linear amides \(\{3.5.1\}\)
9/82 . . . . . . Asparaginase \(\{3.5.1.1\}\)
9/84 . . . . . . Penicillin amidase \(\{3.5.1.11\}\)
9/86 . . . . . . acting on amide bonds in cyclic amides, e.g. penicillinase \(\{3.5.2\}\)
9/88 . . . . . . Lyses (4.)
9/90 . . . . . . Isomerases (5.)
9/92 . . . . . . Glucose isomerase \(\{5.3.1.5; 5.3.1.9; 5.3.1.18\}\)
9/93 . . . . . . [Ligases (6)]
9/94 . . . . . . Pancreatin
9/96 . . . . . . Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
9/98 . . . . . . Preparation of granular or free-flowing enzyme compositions \(\text{C12N 9/96 takes precedence}\)
9/99 . . . . . . Enzyme inactivation by chemical treatment

11/00 Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof

11/02 . . . . . . Enzymes or microbial cells immobilised on or in an organic carrier
11/04 . . . . . . entrapped within the carrier, e.g. gel or hollow fibres
11/06 . . . . . . attached to the carrier via a bridging agent
11/08 . . . . . . the carrier being a synthetic polymer

**WARNING**


All groups listed in this Warning should be considered in order to perform a complete search.
11/082 . . . obtained by reactions only involving carbon-to-carbon unsaturated bonds

**WARNING**


Groups C12N 11/08, C12N 11/082, C12N 11/084 and C12N 11/087 should be considered in order to perform a complete search.

11/084 . . . Polymers containing vinyl alcohol units

11/087 . . . Acrylic polymers

11/089 . . . obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds

**WARNING**


Groups C12N 11/08, C12N 11/089, C12N 11/091, C12N 11/093 and C12N 11/096 should be considered in order to perform a complete search.

11/091 . . . Phenol resins; Amino resins

11/093 . . . Polyurethanes

11/096 . . . Polysteres; Polyanides

11/098 . . . formed in the presence of the enzymes or microbial cells

**WARNING**

Group C12N 11/098 is incomplete pending reclassification of documents from group C12N 11/08.

Groups C12N 11/08 and C12N 11/098 should be considered in order to perform a complete search.

11/10 . . . the carrier being a carbohydrate

11/12 . . . Cellulose or derivatives thereof

11/14 . . . Enzymes or microbial cells immobilised on or in an inorganic carrier

11/16 . . . Enzymes or microbial cells immobilised on or in a biological cell

11/18 . . . Multi-enzyme systems

**13/00**

Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves

15/00

**Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor** (mutants or genetically engineered microorganisms, per se C12N 1/00, C12N 5/00, C12N 7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H 4/00; new animals per se A01K 67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K 48/00)

15/01 . . . Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor

15/02 . . . Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion { monoclonal antibodies C07K 16/00; apparatus for cell fusion C12M }

15/03 . . . Bacteria

15/04 . . . Fungi

15/09 . . . Recombinant DNA-technology

15/10 . . . Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H 21/00; preparation of non-structural polynucleotides from microorganisms or with enzymes C12P 19/34)

**NOTE**

After the symbol C12N 15/10 - C12N 15/1096, and separated therefrom by a + sign, it is desirable to add the indexing codes selected from groups C12Q 2500/00 - C12Q 2565/634, relating to relevant technical features of the invention.

When more than one indexing code is selected, the different codes are separated by a + sign.

Example: C12N 15/1037 + C12Q 2537/125 + C12Q 2521/537

15/1003 . . . [Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor]

15/1006 . . . [by means of a solid support carrier, e.g. particles, polymers]

15/101 . . . [by chromatography, e.g. electrophoresis, ion-exchange, reverse phase]

15/1013 . . . [by using magnetic beads]

15/1017 . . . [by filtration, e.g. using filters, frits, membranes]

15/102 . . . [Mutagenizing nucleic acids]

15/1024 . . . [In vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair]

15/1027 . . . [by DNA shuffling, e.g. RSR, STEP, RPR]

15/1031 . . . [mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR]

15/1034 . . . [Isolating an individual clone by screening libraries]

15/1037 . . . [Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display]

15/1041 . . . [Ribosome/Polysome display, e.g. SPERT, ARM]

15/1044 . . . [Preparation or screening of libraries displayed on scaffold proteins]

15/1048 . . . [SELEX]

15/1051 . . . [Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors]

15/1055 . . . [Protein x Protein interaction, e.g. two hybrid selection]
NOTE

Aptamers fused to compounds which are already classified in groups C12N 15/11 - C12N 15/117, are classified with the corresponding compound.

NOTE

In this group genes encoding for proenzymes are classified with the corresponding genes encoding enzymes.

NOTE

In this group, the following term is used with the meaning indicated:

• "fusion" means the fusion of two different proteins.

NOTE

In this group, the following expression is used with the meaning indicated:

• General methods applicable to biologically active non-coding nucleic acids.
15/67 . . . General methods for enhancing the expression
15/68 . . . . Stabilisation of the vector
15/69 . . . . Increasing the copy number of the vector
15/70 . . . Vectors or expression systems specially adapted for E. coli

**NOTES**
1. This group covers the use of E. coli as host.
2. Shuttle vectors also replicating in E. coli are classified according to the other host.

15/71 . . . Expression systems using regulatory sequences derived from the trp-operon
15/72 . . . Expression systems using regulatory sequences derived from the lac-operon
15/73 . . . Expression systems using phage (lambda) regulatory sequences
15/74 . . . Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

**NOTE**
This group covers the use of prokaryotes as hosts.

15/743 . . . . (for Agrobacterium; Rhizobium; Bradyrhizobium)
15/746 . . . . (for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus))
15/75 . . . for Bacillus
15/76 . . . . for Actinomyces; for Streptomyces
15/77 . . . for Corynebacterium; for Brevibacterium
15/78 . . . . for Pseudomonas
15/79 . . . . Vectors or expression systems specially adapted for eukaryotic hosts

**NOTE**
This group covers the use of eukaryotes as hosts.

15/80 . . . . for fungi
15/81 . . . . for yeasts
15/815 . . . . (for yeasts other than Saccharomyces)
15/82 . . . . for plant cells [, e.g. plant artificial chromosomes (PACs)]

**WARNING**
Documents are being continuously reclassified into this new classification scheme. See Warning notes below

15/8201 . . . . {Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation}
15/8202 . . . . {by biological means, e.g. cell mediated or natural vector}
15/8203 . . . . {Virus mediated transformation}

15/8205 . . . . {Agrobacterium mediated transformation}
15/8206 . . . . {by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated}
15/8207 . . . . {by mechanical means, e.g. microinjection, particle bombardment, silicon whiskers}
15/8209 . . . . {Selection, visualisation of transformants, reporter constructs, e.g. antibiotic resistance markers}

**NOTE**
Standard selectable markers such as neomycin phosphotransferase (NPT) are not systematically classified in C12N 15/8209

15/821 . . . . {Non-antibiotic resistance markers, e.g. morphogenetic, metabolic markers}
15/8212 . . . . {Colour markers, e.g. beta-glucoronidase [GUS], green fluorescent protein [GFP], carotenoid}
15/8213 . . . . {Targeted insertion of genes into the plant genome by homologous recombination}
15/8214 . . . . {Plastid transformation}
15/8216 . . . . {Methods for controlling, regulating or enhancing expression of transgenes in plant cells}
15/8217 . . . . {Gene switch}
15/8218 . . . . {Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]}
15/822 . . . . {Reducing position variability, e.g. by the use of scaffold attachment region/matrix attachment region (SAR/MAR); Use of SAR/MAR to regulate gene expression}
15/8221 . . . . {Transit peptides}
15/8222 . . . . {Developmentally regulated expression systems, tissue, organ specific, temporal or spatial regulation}
15/8223 . . . . {Vegetative tissue-specific promoters}
15/8225 . . . . {Leaf-specific, e.g. including petioles, stomata}
15/8226 . . . . {Stem-specific, e.g. including tubers, beets}
15/8227 . . . . {Root-specific}
15/8229 . . . . {Meristem-specific, e.g. nodal, apical}
15/823 . . . . {Reproductive tissue-specific promoters}
15/8231 . . . . {Male-specific, e.g. anther, tapetum, pollen}
15/8233 . . . . {Female-specific, e.g. pistil, ovule}
15/8234 . . . . {Seed-specific, e.g. embryo, endosperm}
15/8235 . . . . {Fruit-specific}
15/8237 . . . . {Externally regulated expression systems}
plants via recombinant DNA technology}

{ Phenotypically and genetically modified yield }

{ with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits }

{ involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine }

{ involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis }

{ Non-starch polysaccharides, e.g. cellulose, fructans, levans }

{ involving modified lipid metabolism, e.g. seed oil composition }

{ involving ethylene biosynthesis, senescence or fruit development, e.g. modified tomato ripening, cut flower shelf-life }

{ involving pigment biosynthesis }

**NOTE**

Transgenic plants with altered flower morphology are also classified in this group

15/8238 . . . . . . . . . . [chemically inducible, e.g. tetracycline]
15/8239 . . . . . . . . . . [pathogen inducible]
15/8241 . . . . . . . . . . {Phenotypically and genetically modified plants via recombinant DNA technology}
15/8242 . . . . . . . . . . {with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits}
15/8243 . . . . . . . . . . {involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine}
15/8245 . . . . . . . . . . {involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis}
15/8246 . . . . . . . . . . {Non-starch polysaccharides, e.g. cellulose, fructans, levans}
15/8247 . . . . . . . . . . {involving modified lipid metabolism, e.g. seed oil composition}
15/8249 . . . . . . . . . . {involving ethylene biosynthesis, senescence or fruit development, e.g. modified tomato ripening, cut flower shelf-life}
15/825 . . . . . . . . . . {involving pigment biosynthesis}

**NOTE**

Transgenic plants with altered flower morphology are also classified in this group

15/8251 . . . . . . . . . . {Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis}
15/8253 . . . . . . . . . . {Methionine or cysteine}
15/8254 . . . . . . . . . . {Tryptophan or lysine}
15/8255 . . . . . . . . . . {involving lignin biosynthesis}
15/8257 . . . . . . . . . . {for the production of primary gene products, e.g. pharmaceutical products, interferon}
15/8258 . . . . . . . . . . {for the production of oral vaccines (antigens) or immunoglobulins}
15/8259 . . . . . . . . . . {Phytoremediation}
15/8261 . . . . . . . . . . {with agronomic (input) traits, e.g. crop yield}
15/8262 . . . . . . . . . . {involving plant development (not used)}
15/8263 . . . . . . . . . . {Ablation; Apoptosis}
15/8265 . . . . . . . . . . {Transgene containment, e.g. gene dispersal}
15/8266 . . . . . . . . . . {Abscission; Dehiscence; Senescence}
15/8267 . . . . . . . . . . {Seed dormancy, germination or sprouting}
15/8269 . . . . . . . . . . {Photosynthesis}
15/827 . . . . . . . . . . {Flower development or morphology, e.g. flowering promoting factor [FPF]}
15/8271 . . . . . . . . . . {for stress resistance, e.g. heavy metal resistance}
15/8273 . . . . . . . . . . {for drought, cold, salt resistance}
15/8274 . . . . . . . . . . {for herbicide resistance}
15/8275 . . . . . . . . . . {Glyphosate}
15/8277 . . . . . . . . . . {Phosphinotricin}
15/8278 . . . . . . . . . . {Sulfonylurea}
15/8279 . . . . . . . . . . {for biotic stress resistance, pathogen resistance, disease resistance}
15/8281 . . . . . . . . . . {for bacterial resistance}
15/8282 . . . . . . . . . . {for fungal resistance}
15/8283 . . . . . . . . . . {for virus resistance}
15/8285 . . . . . . . . . . {for nematode resistance}
15/8286 . . . . . . . . . . {for insect resistance}
15/8287 . . . . . . . . . . {for fertility modification, e.g. apomixis}
15/8289 . . . . . . . . . . {Male sterility}
15/829 . . . . . . . . . . {Female sterility}
15/8291 . . . . . . . . . . {Hormone-influenced development}
15/8293 . . . . . . . . . . {Abscisic acid [ABA]}
15/8294 . . . . . . . . . . {Auxins}
15/8295 . . . . . . . . . . {Cytokinins}
15/8297 . . . . . . . . . . {Gibberellins: GA3}
15/8298 . . . . . . . . . . {Brassinosteroids}
15/85 . . . . . . . . . . {for animal cells}
15/8509 . . . . . . . . . . {for producing genetically modified animals, e.g. transgenic}

**NOTE**

Additional aspects of the modified animals are classified in the groups A01K 2207/00 - A01K 2267/00

2015/8518 . . . . . . . . . . {expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles}
2015/8527 . . . . . . . . . . {for producing animal models, e.g. for tests or diseases}
2015/8536 . . . . . . . . . . {Animal models for genetic diseases}
2015/8545 . . . . . . . . . . {for Alzheimer’s disease}
2015/8554 . . . . . . . . . . {Invertebrates models for Alzheimer’s disease}
2015/8563 . . . . . . . . . . {for autoimmune diseases, e.g. Insulin-dependent diabetes mellitus}
2015/8572 . . . . . . . . . . {Animal models for proliferative diseases, e.g. comprising an oncogene}
2015/8581 . . . . . . . . . . {Animal models for infectious diseases, e.g. AIDS}
2015/859 . . . . . . . . . . {Animal models comprising reporter system for screening tests}
15/86 . . . . . . . . . . {Viral vectors}

**WARNING**

From March 15, 2012 groups C12N 15/861 - C12N 15/869 and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range C12N 2710/00-C12N 2795/00

15/861 . . . . . . . . . . {Adenoviral vectors}
15/8613 . . . . . . . . . . {Chimaeric vector systems comprising heterologous sequences for production of another viral vector}
15/8616 . . . . . . . . . . {Special methods for targeting systems}
15/863 . . . . . . . . . . . . Poxviral vectors, [e.g. entomopoxivirus]
15/8633 . . . . . . . . . . [Avian poxviral vectors]
15/8636 . . . . . . . . . . [Vaccina virus vectors]
15/864 . . . . . . . . . . Paroviral vectors, { e.g. parvovirus, densovirus}
15/8645 . . . . . . . . . . [Adeno-associated virus]
15/866 . . . . . . . . . . Baculoviral vectors
15/867 . . . . . . . . . . Retroviral vectors
15/8673 . . . . . . . . . . [Special methods for packaging systems]
15/8676 . . . . . . . . . . [Special methods for targeting systems]
15/869 . . . . . . . . . . Herpesviral vectors
15/8695 . . . . . . . . . . [Herpes simplex virus-based vectors]
15/87 . . . . . . . . . . Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
15/873 . . . . . . . . . . Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
15/877 . . . . . . . . . . Techniques for producing new mammalian cloned embryos
15/8771 . . . . . . . . . . [Bovine embryos]
15/8772 . . . . . . . . . . [Caprine embryos]
15/8773 . . . . . . . . . . [Ovine embryos]
15/8775 . . . . . . . . . . [Murne embryos]
15/8776 . . . . . . . . . . [Primate embryos]
15/8777 . . . . . . . . . . [Rabbit embryos]
15/8778 . . . . . . . . . . [Swine embryos]
15/88 . . . . . . . . . . using microencapsulation, e.g. using amphiphile liposome vesicle
15/89 . . . . . . . . . . using microinjection
15/895 . . . . . . . . . . [using biologic methods]
15/90 . . . . . . . . . . Stable introduction of foreign DNA into chromosome
15/902 . . . . . . . . . . [using homologous recombination]
15/905 . . . . . . . . . . [in yeast]
15/907 . . . . . . . . . . [in mammalian cells]

2303/00 Indexing codes associated with general methodologies in the field of biologically active non-coding nucleic acids

NOTE

Indexing codes of group C12N 2303/00 are only used in combination with group C12N 15/111

2310/00 Structure or type of the nucleic acid

2310/10 . . . . . . . . . . Type of nucleic acid
2310/11 . . . . . . . . . . Antisense
2310/111 . . . . . . . . . . spanning the whole gene, or a large part of it
2310/113 . . . . . . . . . . targeting other non-coding nucleic acids, e.g. antagonirs
2310/12 . . . . . . . . . . catalytic nucleic acids, e.g. ribozymes
2310/121 . . . . . . . . . . Hammerhead
2310/122 . . . . . . . . . . Hairpin
2310/123 . . . . . . . . . . Hepatitis delta
2310/124 . . . . . . . . . . based on group I or II introns
2310/1241 . . . . . . . . . . Tetrahymena
2310/126 . . . . . . . . . . involving RNase P
2310/127 . . . . . . . . . . DNAzymes
2310/128 . . . . . . . . . . processing or releasing ribozyme
2310/13 . . . . . . . . . . Decoys
2310/14 . . . . . . . . . . interfering N.A.
2310/141 . . . . . . . . . . MicroRNAs, miRNAs
2310/15 . . . . . . . . . . Nucleic acids forming more than 2 strands, e.g. TFOs
2310/151 . . . . . . . . . . more than 3 strands, e.g. tetrads, H-DNA
2310/152 . . . . . . . . . . on a single-stranded target, e.g. fold-back TFOs
2310/153 . . . . . . . . . . with the aid of a protein, e.g. recombinase
2310/16 . . . . . . . . . . Aptamers
2310/17 . . . . . . . . . . Immunomodulatory nucleic acids
2310/18 . . . . . . . . . . acting by a non-sequence specific mechanism (other than C12N 2310/16 or C12N 2310/17)
2310/20 . . . . . . . . . . involving clustered regularly interspaced short palindromic repeats [CRISPRs]
2310/30 . . . . . . . . . . Chemical structure
2310/31 . . . . . . . . . . of the backbone
2310/311 . . . . . . . . . . Phosphotriesters
2310/312 . . . . . . . . . . Phosphonates
2310/3125 . . . . . . . . . . Methylphosphonates
2310/313 . . . . . . . . . . Phosphorodithioates
2310/314 . . . . . . . . . . Phosphoramidates
2310/3145 . . . . . . . . . . with the nitrogen in 3’ or 5’-position
2310/315 . . . . . . . . . . Phosphorothioates
2310/316 . . . . . . . . . . Phosphonothioates
2310/317 . . . . . . . . . . with an inverted bond, e.g. a cap structure
2310/318 . . . . . . . . . . where the PO2 is completely replaced, e.g. MMI or formacetal
2310/3181 . . . . . . . . . . Peptide nucleic acid, PNA
2310/3183 . . . . . . . . . . Diol linkers, e.g. glycols or propanediols
2310/319 . . . . . . . . . . linked by 2’-3’ linkages, i.e. having a free 3’-position
2310/32 . . . . . . . . . . of the sugar
2310/321 . . . . . . . . . . 2’-O-R Modification
2310/322 . . . . . . . . . . 2’-R Modification
2310/323 . . . . . . . . . . modified ring structure
2310/3231 . . . . . . . . . . having an additional ring, e.g. LNA, ENA
2310/3233 . . . . . . . . . . Morpholino-type ring
2310/3235 . . . . . . . . . . having the O of the ribose replaced by another atom
2310/33 . . . . . . . . . . of the base
2310/331 . . . . . . . . . . Universal or degenerate base
2310/332 . . . . . . . . . . Abasic residue
2310/333 . . . . . . . . . . Modified A
2310/334 . . . . . . . . . . Modified C
2310/3341 . . . . . . . . . . 5-Methylcytosine
2310/335 . . . . . . . . . . Modified T or U
2310/336 . . . . . . . . . . Modified G
2310/337 . . . . . . . . . . in alpha-anomeric form
2310/34 . . . . . . . . . . Spatial arrangement of the modifications
2310/341 . . . . . . . . . . Gampers, i.e. of the type ========
2310/342 . . . . . . . . . . Hemimers, i.e. of the type ========
2310/343 . . . . . . . . . . having patterns, e.g. ==-----==
2310/344 . . . . . . . . . . Position-specific modifications, e.g. on every purine, at the 3’-end
2310/345 . . . . . . . . . . having at least two different backbone modifications
2310/346 . . . . . . . . . . having a combination of backbone and sugar modifications
2310/35 . . . . . . . . . . Nature of the modification
2310/351 . . . . . . . . . . Conjugate
2310/3511 . . . . . . . . . . intercalating or cleaving agent
2310/3513 . . . . . . . . . . Protein; Peptide
2310/3515 . . . . . . . . . . Lipophilic moiety, e.g. cholesterol
Specific components of cell culture medium

**2310/51**
- Methyl
- Allyl
- MOE, methoxyethoxy
- Other alkyl chain
- Aromatic substituent
- linked to the nucleic acid via an atom other than carbon
- Hydrogen
- Halogen
- Nitrogen
- Physical structure
- in polymeric form, e.g. multimers, concatamers
- branched
- partially self-complementary or closed
- Stem-loop; Hairpin
- Closed or circular
- having a mismatch or nick in at least one of the strands

**2310/52**
- Transition metals
  - Mg (Magnesium)
- Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- Calcium; Ca chelators; Calcitomin
- Magnesium; Mg chelators
- Transition metals
- Zinc; Zn chelators (insulin-zinc complexes C12N 2500/98)
- Iron; Fe chelators; Transferrin

**2310/53**
- Metals; Metal chelators (cobalamine C12N 2500/38)
- Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- Calcium; Ca chelators; Calcitomin
- Magnesium; Mg chelators
- Transition metals
- Zinc; Zn chelators (insulin-zinc complexes C12N 2500/33)
- Iron; Fe chelators; Transferrin

**2310/54**
- Organic phosphate, e.g. beta glycerophosphate
- Thiols, e.g. mercaptoethanol
- Amines, e.g. putrescine
- Soluble polymers, e.g. polyethyleneglycol [PEG]
- Buffer, e.g. pH regulation, osmotic pressure
- DMSO
- Undefined extracts (conditioned medium C12N 2502/00)

**2310/55**
- from bacteria
- from fungi, e.g. yeasts
- from plants
- from protozoa
- from animals
- from invertebrates
- from mammals
- Serum-free medium, which may still contain naturally-sourced components
- Medium free of human- or animal-derived components
- Protein-free medium and culture conditions
- Xeno-free medium and culture conditions
- Serum-free medium

**2310/56**
- Marker; Tag
- for the determination of target sites, i.e. of active nucleic acids
- in functional genomics, i.e. for the determination of gene function
- in a process of directed evolution, e.g. SELEX, acquiring a new function
- Special therapeutic applications
- Combination therapy
- Special delivery means, e.g. tissue-specific
- Alteration of splicing
- Allele or polymorphism specific uses
- based on a specific dosage / administration regimen
- Methods for regulating/modulating their activity
- modulating the chemical stability, e.g. nuclease-resistance
- modulating the physical stability, e.g. GC-content
- reducing unwanted side-effects

**2310/57**
- naturally occurring
- chemically synthesised
- Libraries, arrays
- Biochemical production, i.e. in a transformed host cell
- Specially adapted vectors

**2320/00**
- Atmosphere, e.g. low oxygen conditions
- Inorganic components
- Metals; Metal chelators (cobalamine C12N 2500/38)
- Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- Calcium; Ca chelators; Calcitomin
- Magnesium; Mg chelators
- Transition metals
- Zinc; Zn chelators (insulin-zinc complexes C12N 2500/33)
- Iron; Fe chelators; Transferrin
- Organic components (metal chelators C12N 2500/10; calcitonin C12N 2500/14; transferrin C12N 2500/24)
- Amino acids
- other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
- Sugars
- Polyols, e.g. glycerin, inositol
- Lipids
- Vitamins
- Nucleotides, nucleosides, bases (cyclic nucleotides C12N 2501/01, anti-neoplastic drugs C12N 2501/06)
- Organic phosphate, e.g. beta glycerophosphate
- Thiols, e.g. mercaptoethanol
- Amines, e.g. putrescine
- Soluble polymers, e.g. polyethyleneglycol [PEG]
- Buffer, e.g. pH regulation, osmotic pressure
- DMSO
- undefined extracts (conditioned medium C12N 2502/00)

**2330/00**
- from bacteria
- from fungi, e.g. yeasts
- from plants
- from protozoa
- from animals
- from invertebrates
- from mammals
- Serum-free medium, which may still contain naturally-sourced components
- Medium free of human- or animal-derived components
- Protein-free medium and culture conditions
- Xeno-free medium and culture conditions
- Serum-free medium

**2500/00**
- Atmosphere, e.g. low oxygen conditions
- Inorganic components
- Metals; Metal chelators (cobalamine C12N 2500/38)
- Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- Calcium; Ca chelators; Calcitomin
- Magnesium; Mg chelators
- Transition metals
- Zinc; Zn chelators (insulin-zinc complexes C12N 2500/33)
- Iron; Fe chelators; Transferrin
- Organic components (metal chelators C12N 2500/10; calcitonin C12N 2500/14; transferrin C12N 2500/24)
- Amino acids
- other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
- Sugars
- Polyols, e.g. glycerin, inositol
- Lipids
- Vitamins
- Nucleotides, nucleosides, bases (cyclic nucleotides C12N 2501/01, anti-neoplastic drugs C12N 2501/06)
- Organic phosphate, e.g. beta glycerophosphate
- Thiols, e.g. mercaptoethanol
- Amines, e.g. putrescine
- Soluble polymers, e.g. polyethyleneglycol [PEG]
- Buffer, e.g. pH regulation, osmotic pressure
- DMSO
- undefined extracts (conditioned medium C12N 2502/00)

**2501/00**
Active agents used in cell culture processes, e.g. differentiation

**NOTE**
Whenever possible, indexation is done by signalling pathway and not by chemical structure, e.g. the group of a protein covers not only peptide analogs of it and the corresponding nucleic acids, as in C07K 14/00, but also antibodies, anti-idiotypic antibodies, non-peptide ligands of the receptor, the receptor itself, antibodies against the receptor or inhibitors of the conversion enzyme which processes the protein precursor. Unless otherwise provided for, ligands and substrates take precedence over receptors and enzymes.

**2501/01**
- Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
- Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
Cytokines; Chemokines

- Heat shock proteins
- Modulators of histone acetylation
- Interleukins \( \text{IL} \)
- Colony stimulating factors (G-CSF, GM-CSF)
- Interleukin-11 (IL-11)
- Interleukin-10 (IL-10)
- Interleukin-9 (IL-9)
- Interleukin-8 (IL-8)
- Interleukin-6 (IL-6)
- Interleukin-5 (IL-5)
- Interleukin-4 (IL-4)
- Interleukin-3 (IL-3)
- Interleukin-2 (IL-2)
- Interleukin-1 (IL-1)

- Growth factors
- Insulin-like growth factors [IGF]
- Epidermal growth factor [EGF]
- Acidic fibroblast growth factor (aFGF, FGF-1)
- Basic fibroblast growth factor (bFGF, FGF-2)
- Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
- Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- Hepatocyte growth factor [HGF]
- Stem cell factor [SCF], c-kit ligand [KL]
- Nerve growth factor [NGF]; Brain-derived neurotrophic factor (BDNF); Ciliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
- Bone morphogenetic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- Activin; Inhibin; Mullerian inhibiting substance
- Vascular endothelial growth factor [VEGF]
- Angiopoietin
- Cardiotrophin
- Growth and differentiation factors [GDF]
- Heregulin, neu differentiation factor
- Cytokines; Chemokines
- Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4

Other fibroblast growth factors

- Parathyroid hormone [PTH]
- Thyroid stimulating hormone [TSH]
- with nuclear receptors
- Tumour necrosing factors [TNF]
- Tumor necrosis factor [TNF]
- Tumour necrosing factor [TNF]
- Thrombopoietin [TPO]
- Erythropoietin [EPO]
- Insulin (together with transferrin C12N 2500/25; Insulin-like growth factors C12N 2500/105)

- Growth hormone [GH], aka. somatotropin
- Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins
- Prolactin
- Angiotensins [AT], angiotensinogen
- Insulin (C12N 2500/25; Insulin-like growth factors C12N 2500/105)
- Glucagon; Glucagon-like peptide [GLP]; Exendin
- Calcitonin; Calcitonin-like related peptide [CGR]; Amylin
- Gastrin; Cholecystokins [CCK]
- Vasoactive intestinal peptide [VIP]; Pituitary adenylate cyclase activating polypeptide [PACAP]
- Leptin
- Somatostatin
- Endothelin

- Parathyroid hormone [PTH]
- Thyroid stimulating hormone [TSH]

- of the family of the retinoic acid receptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]

- Steroid hormones
- Sexual steroids
- Thyroid hormones

- Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
- Hedgehog proteins; Cyclopamine (inhibitor)
- Wnt; Frizzled
- Notch; Delta; Jagged; Serrate
C12N

2501/48 . . . Regulators of apoptosis
2501/50 . . . Cell markers; Cell surface determinants
2501/505 . . . CD4; CD8
2501/51 . . . B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
2501/515 . . . CD3, T-cell receptor complex
2501/52 . . . CD40, CD40-ligand (CD154)
2501/53 . . . CD2
2501/58 . . . Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
2501/585 . . . Integrins
2501/59 . . . Lectins
2501/599 . . . with CD designations not provided for elsewhere
2501/60 . . . Transcription factors
2501/602 . . . Sox-2
2501/603 . . . Oct-3/4
2501/604 . . . Klf-4
2501/605 . . . Nanog
2501/606 . . . c-Myc
2501/608 . . . Lin28
2501/65 . . . MicroRNA
2501/70 . . . Enzymes
2501/71 . . . Oxidoreductases (EC 1.)
2501/72 . . . Transferases (EC 2.) (acetylation of histones C12N 2501/065)
2501/724 . . . Glycosyltransferases (EC 2.4.)
2501/727 . . . Kinases (EC 2.7.)
2501/73 . . . Hydrolases (EC 3.)
2501/734 . . . Proteases (EC 3.4.)
2501/80 . . . Neurotransmitters; Neurohormones
2501/805 . . . Acetylcholine
2501/81 . . . Adrenaline
2501/815 . . . Dopamine
2501/82 . . . Histamine
2501/825 . . . Serotonin (5-HT); Melatonin
2501/83 . . . Tachykinins, e.g. substance P
2501/835 . . . Neuropeptide Y [NPY]; Peptide YY [PYY]
2501/84 . . . Excitatory amino acids
2501/845 . . . Gamma amino butyric acid [GABA]
2501/85 . . . Hormones derived from pro-opiomelanocortin, proenkephalin or pro-dynorphin
2501/855 . . . Corticotropin [ACTH]
2501/86 . . . Melanocyte-stimulating hormone [MSH]
2501/90 . . . Polysaccharides
2501/905 . . . Hyaluronic acid
2501/91 . . . Heparin
2501/998 . . . Proteins not provided for elsewhere

NOTE
Classification by pathway does not apply.

2501/999 . . . Small molecules not provided for elsewhere

NOTE
Classification by pathway does not apply.

2502/00 . . . Coculture with; Conditioned medium produced by
2502/02 . . . embryonic cells
2502/025 . . . extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton’s jelly
2502/03 . . . non-embryonic pluripotent stem cells
2502/04 . . . germ cells
2502/07 . . . endocrine cells
2502/072 . . . adrenal cells
2502/074 . . . pinealocytes
2502/076 . . . pituitary cells
2502/078 . . . thyroid, parathyroid cells
2502/08 . . . cells of the nervous system
2502/081 . . . neurons
2502/083 . . . sensory transducers
2502/085 . . . eye cells
2502/086 . . . glial cells
2502/088 . . . neural stem cells
2502/09 . . . epidermal cells, skin cells, oral mucosa cells
2502/091 . . . melanocytes
2502/092 . . . hair cells
2502/094 . . . keratinocytes
2502/095 . . . mammary cells
2502/097 . . . oral mucosa cells
2502/098 . . . cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrimal glands
2502/11 . . . blood or immune system cells
2502/1107 . . . B cells
2502/1114 . . . T cells
2502/1121 . . . Dendritic cells
2502/1128 . . . Erythrocytes
2502/1135 . . . Granulocytes
2502/1142 . . . Osteoclasts
2502/115 . . . Platelets, megakaryocytes
2502/1157 . . . Monocytes, macrophages
2502/1164 . . . NK cells
2502/1171 . . . Haematopoietic stem cells
2502/1178 . . . Spleen cells
2502/1185 . . . Thymus cells
2502/1192 . . . Lymphatic cells
2502/13 . . . connective tissue cells; generic mesenchyme cells, e.g. so-called “embryonic fibroblasts”
2502/1305 . . . Adipocytes
2502/1311 . . . Osteocytes, osteoblasts, odontoblasts
2502/1317 . . . Chondrocytes
2502/1323 . . . Adult fibroblasts
2502/1329 . . . Cardiomyocytes
2502/1335 . . . Skeletal muscle cells, myocytes, myoblasts, myotubes
2502/1341 . . . Tenocytes, cells from tendons and ligaments
2502/1347 . . . Smooth muscle cells
2502/1352 . . . Mesenchymal stem cells
2502/1358 . . . Bone marrow mesenchymal stem cells (BM-MSC)
2502/1364 . . . Dental pulp stem cells, dental follicle stem cells
2502/1367 . . . Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood
2502/1376 . . . Mesenchymal stem cells from hair follicles
2502/1382 . . . Adipose-derived stem cells [ADSC], adipose stromal stem cells
2502/1388 . . . Mesenchymal stem cells from other natural sources
2502/1394 . . . Bone marrow stromal cells; whole marrow
2502/14 . . . hepatocytes
2502/22 . . . pancreatic cells
2502/23 . . . Gastro-intestinal tract cells
2502/24 . . . Genital tract cells, non-germinal cells from gonads
2502/243 . . . Cells of the female genital tract, non-germinal ovarian cells
2502/246 . Cells of the male genital tract, non-germinal testis cells
2502/25 . Urinary tract cells, renal cells
2502/253 . Bladder cells
2502/256 . Renal cells
2502/27 . Lung cells, respiratory tract cells
2502/28 . Vascular endothelial cells
2502/30 . tumour cells
2502/45 . Artificially induced pluripotent stem cells
2502/50 . invertebrate cells
2502/70 . Non-animal cells
2502/99 . genetically modified cells

**NOTE**

Use C12N 2501/00 to index the expressed products.

2503/00 Use of cells in diagnostics
2503/02 . Drug screening
2503/04 . Screening or testing on artificial tissues
2503/06 . Screening or testing on artificial skin

**2506/00 Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells**

**NOTE**

This scheme indexes the starting point of a differentiation process and is used in combination with classification in C12N 5/06 for the end product. Differentiation of a restricted progenitor cell into its expected progeny is not indexed. Differentiation of totipotent cells and dedifferentiation are always indexed.

2506/02 . from embryonic cells
2506/025 . from extra-embryonic cells, e.g. trophoblast, placenta
2506/03 . from non-embryonic pluripotent stem cells
2506/04 . from germ cells
2506/07 . from endocrine cells
2506/072 . from adrenal cells
2506/074 . from pinealocytes
2506/076 . from pituitary cells
2506/078 . from thyroid, parathyroid cells
2506/08 . from cells of the nervous system
2506/09 . from epidermal cells, from skin cells, from oral mucosa cells
2506/091 . from melanocytes
2506/092 . from hair cells
2506/094 . from keratinocytes
2506/095 . from mammary cells
2506/097 . from oral mucosa cells
2506/098 . from cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrimal glands
2506/11 . from blood or immune system cells
2506/115 . from monocytes, from macrophages
2506/13 . from connective tissue cells, from mesenchymal cells
2506/1307 . from adult fibroblasts
2506/1315 . from cardiomyocytes
2506/1323 . from skeletal muscle cells
2506/133 . from tenocytes
2506/1338 . from smooth muscle cells
2506/1346 . from mesenchymal stem cells

2506/1353 . from bone marrow mesenchymal stem cells (BM-MSC)
2506/1361 . from dental pulp or dental follicle stem cells
2506/1369 . from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood
2506/1376 . from mesenchymal stem cells derived from hair follicles
2506/1384 . from adipose-derived stem cells [ADSC], from adipose stromal stem cells
2506/1392 . from mesenchymal stem cells from other natural sources
2506/14 . from hepatocytes
2506/22 . from pancreatic cells
2506/23 . from cells of the gastro-intestinal tract
2506/24 . from cells of the genital tract, from non-germinal gonad cells
2506/243 . from cells of the female genital tract cells, from non-germinal ovarian cells
2506/246 . from cells of the male genital tract cells, from non-germinal testis cells
2506/25 . from renal cells, from cells of the urinary tract
2506/27 . from lung cells, from cells of the respiratory tract
2506/28 . from vascular endothelial cells
2506/30 . from cancer cells, e.g. reversion of tumour cells

**NOTE**

Unless the tumourigenic phenotype is totally reversed, the end product is still classified under C12N 5/0693.

2506/45 . from artificially induced pluripotent stem cells

**2509/00 Methods for the dissociation of cells, e.g. specific use of enzymes**

2509/10 . Mechanical dissociation

**2510/00 Genetically modified cells**

2510/02 . Cells for production
2510/04 . Immortalised cells

**2511/00 Cells for large scale production**

**2513/00 3D culture**

**2517/00 Cells related to new breeds of animals**

2517/02 . Cells from transgenic animals
2517/04 . Cells produced using nuclear transfer
2517/10 . Conditioning of cells for in vitro fecondation or nuclear transfer

**2521/00 Culture process characterised by the use of hydrostatic pressure, flow or shear forces**

2521/10 . Sound, e.g. ultrasounds

**2523/00 Culture process characterised by temperature**

**2525/00 Culture process characterised by gravity, e.g. microgravity**

**2527/00 Culture process characterised by the use of mechanical forces, e.g. strain, vibration**

**2529/00 Culture process characterised by the use of electromagnetic stimulation**

2529/10 . Stimulation by light

**2531/00 Microcarriers**
Supports or coatings for cell culture, characterised by material

- Mineral substrates
- Glass
- Ceramic
- Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells
- Small organic molecules
- Synthetic polymers (thermoreactive polymers, e.g. PNIPAm, C12N 2539/10)
- Polylsine, polynornithine
- Polyoxyhydroxycids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioreosorbable polymers
- Proteins
- Fibronectin; Laminin
- Collagen; Gelatin
- Fibrin; Thrombin
- Polysaccharides
- Chitin, chitosan
- Alginate
- Agarose, agar-agar
- Cellulose
- Hyaluronan
- Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- Amnion; Decellularised dermis or mucosa

Supports or coatings for cell culture, characterised by topography

- Patterned coating

Supports and/or coatings for cell culture, characterised by physical or chemical treatment

- Cross-linking

Supports and/or coatings for cell culture, characterised by properties

- Coating allowing for selective detachment of cells, e.g. thermoreactive coating

Viruses

- dsDNA Viruses (not used)
- Viruses as such, e.g. new isolates, mutants or their genomic sequences
- New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Virus like particles [VLP]
- Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Use of virus, viral particle or viral elements as a vector
- Virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- Special targeting system for viral vectors
- Methods of production or purification of viral material
- relating to complementing cells and packaging systems for producing virus or viral particles
- Methods of inactivation or attenuation
- by genetic engineering
- by chemical treatment
- by serial passage
- Demonstrated in vivo effect
- For redistribution
- Atadenovirus, e.g. ovine adenovirus D
- Viruses as such, e.g. new isolates, mutants or their genomic sequences
- New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Virus like particles [VLP]
- Uses of virus other than therapeutic or vaccine, e.g. disinfectant
Methods of inactivation or attenuation

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Aviadenovirus, e.g. fowl adenovirus A

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. as cytolytic agent

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Asfarviridae

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. as cytolytic agent

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Asfarviridae

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. as cytolytic agent

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Asfarviridae

Viruses as such, e.g. new isolates, mutants or their genomic sequences
Baculoviridae

Methods of production or purification of viral material

2710/14051 . . . Methods of production or purification of viral material

2710/14052 . . . relating to complementing cells and packaging systems for producing virus or viral particles

2710/14061 . . . Methods of inactivation or attenuation

2710/14062 . . . by genetic engineering

2710/14063 . . . by chemical treatment

2710/14064 . . . by serial passage

2710/14071 . . . Demonstrated in vivo effect

2710/14088 . . . For redistribution

2710/14091 . . . viruses as such, e.g. new isolates, mutants or their genomic sequences

2710/14092 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

2710/14093 . . . Virus like particles [VLP]

2710/14094 . . . Viruses as such, e.g. live-attenuated or inactivated virus, VLP, viral protein

2710/14095 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

2710/14096 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

2710/14097 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

2710/14098 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector

2710/14099 . . . Special targeting system for viral vectors

2710/14100 . . . Methods of production or purification of viral material

2710/14101 . . . relating to complementing cells and packaging systems for producing virus or viral particles

2710/14102 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences

2710/14103 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

2710/14104 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector

2710/14105 . . . Special targeting system for viral vectors

2710/14106 . . . Methods of production or purification of viral material

2710/14107 . . . relating to complementing cells and packaging systems for producing virus or viral particles

2710/14108 . . . For redistribution

2710/14109 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences

2710/14110 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

2710/14111 . . . Virus like particles [VLP]

2710/14112 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences

2710/14113 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

2710/14114 . . . Virus like particles [VLP]
Epstein-Barr Virus
Lymphocryptovirus, e.g. human herpesvirus 4,
Cytomegalovirus, e.g. human herpesvirus 5

- Demonstrated in vivo effect
- For redistribution
- Virus as such, e.g. new isolates, mutants or their genomic sequences
- New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Virus like particles [VLP]
- Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- Use of viral protein as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Viruses as such, e.g. new isolates, mutants or their genomic sequences
- New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- Use of viral protein as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- For redistribution
- Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- Viruses as such, e.g. new isolates, mutants or their genomic sequences
- New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- Use of viral protein as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- For redistribution
- Viruses like particles [VLP]
- Methods of production or purification of viral material
- relating to complementing cells and packaging systems for producing virus or viral particles
- Methods of inactivation or attenuation
- by genetic engineering
- by chemical treatment
- by serial passage
- Demonstrated in vivo effect
- For redistribution
- Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- Viruses as such, e.g. new isolates, mutants or their genomic sequences
- New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Virus like particles [VLP]
- Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- Use of viral protein as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Use of virus, viral particle or viral elements as a vector
- Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- Special targeting system for viral vectors
- Methods of production or purification of viral material
- relating to complementing cells and packaging systems for producing virus or viral particles
- Methods of inactivation or attenuation
- by genetic engineering
- by chemical treatment
- by serial passage
- Demonstrated in vivo effect
- For redistribution
- Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- Special targeting system for viral vectors
- Methods of production or purification of viral material
- relating to complementing cells and packaging systems for producing virus or viral particles
- Methods of inactivation or attenuation
- by genetic engineering
- by chemical treatment
- by serial passage
- Demonstrated in vivo effect
- For redistribution
- Rhadinovirus, e.g. human herpesvirus 8
- Viruses as such, e.g. new isolates, mutants or their genomic sequences
- New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16423 . . . . . . . Virus like particles [VLP]
2710/16431 . . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16432 . . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/16433 . . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/16434 . . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/16441 . . . . . . . Use of virus, viral particle or viral elements as a vector
2710/16442 . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/16443 . . . . . . . viral genome or elements thereof as genetic vector
2710/16444 . . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/16445 . . . . . . . Special targeting system for viral vectors
2710/16451 . . . . . . . Methods of production or purification of viral material
2710/16452 . . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/16461 . . . . . . . Methods of inactivation or attenuation
2710/16462 . . . . . . . by genetic engineering
2710/16463 . . . . . . . by chemical treatment
2710/16464 . . . . . . . by serial passage
2710/16471 . . . . . . . Demonstrated in vivo effect
2710/16488 . . . . . . . For redistribution
2710/16511 . . . . . . . Roseolovirus, e.g. human herpesvirus 6, 7
2710/16521 . . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16522 . . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16523 . . . . . . . Virus like particles [VLP]
2710/16531 . . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16532 . . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/16533 . . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/16534 . . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/16541 . . . . . . . Use of virus, viral particle or viral elements as a vector
2710/16542 . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/16543 . . . . . . . viral genome or elements thereof as genetic vector
2710/16544 . . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/16545 . . . . . . . Special targeting system for viral vectors
2710/16551 . . . . . . . Methods of production or purification of viral material
2710/16552 . . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/16561 . . . . . . . Methods of inactivation or attenuation
2710/16562 . . . . . . . by genetic engineering
2710/16563 . . . . . . . by chemical treatment
2710/16564 . . . . . . . by serial passage
2710/16571 . . . . . . . Demonstrated in vivo effect
2710/16588 . . . . . . . For redistribution
2710/16611 . . . . . . . Simplexvirus, e.g. human herpesvirus 1, 2
2710/16621 . . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16622 . . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16623 . . . . . . . Virus like particles [VLP]
2710/16631 . . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16632 . . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/16633 . . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/16634 . . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/16641 . . . . . . . Use of virus, viral particle or viral elements as a vector
2710/16642 . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/16643 . . . . . . . viral genome or elements thereof as genetic vector
2710/16644 . . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/16645 . . . . . . . Special targeting system for viral vectors
2710/16651 . . . . . . . Methods of production or purification of viral material
2710/16652 . . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/16661 . . . . . . . Methods of inactivation or attenuation
2710/16662 . . . . . . . by genetic engineering
2710/16663 . . . . . . . by chemical treatment
2710/16664 . . . . . . . by serial passage
2710/16671 . . . . . . . Demonstrated in vivo effect
2710/16688 . . . . . . . For redistribution
2710/16711 . . . . . . . Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
2710/16721 . . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16722 . . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16723 . . . . . . . Virus like particles [VLP]
2710/16731 . . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16732 . . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/16733 . . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/16734 . . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/16741 . . . . . . . Use of virus, viral particle or viral elements as a vector
2710/16742 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/16743 . . . . . viral genome or elements thereof as genetic vector
2710/16744 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/16745 . . . . . Special targeting system for viral vectors
2710/16751 . . . . . Methods of production or purification of viral material
2710/16752 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/16761 . . . . . Methods of inactivation or attenuation
2710/16762 . . . . . by genetic engineering
2710/16763 . . . . . by chemical treatment
2710/16764 . . . . . by serial passage
2710/16771 . . . . . Demonstrated in vivo effect
2710/16788 . . . . . For redistribution
2710/18011 . . . . . Nimaviridae
2710/18021 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/18022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/18023 . . . . . Virus like particles [VLP]
2710/18031 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/18032 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytotytic agent
2710/18033 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/18034 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/18041 . . . . . Use of virus, viral particle or viral elements as a vector
2710/18042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/18043 . . . . . viral genome or elements thereof as genetic vector
2710/18044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/18045 . . . . . Special targeting system for viral vectors
2710/18051 . . . . . Methods of production or purification of viral material
2710/18052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2710/18061 . . . . . Methods of inactivation or attenuation
2710/18062 . . . . . by genetic engineering
2710/18063 . . . . . by chemical treatment
2710/18064 . . . . . by serial passage
2710/18071 . . . . . Demonstrated in vivo effect
2710/18088 . . . . . For redistribution
2710/20011 . . . . . Papillomaviridae
2710/20021 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/20022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/20023 . . . . . Virus like particles [VLP]
<table>
<thead>
<tr>
<th>CPC Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2710/22062</td>
<td>by genetic engineering</td>
</tr>
<tr>
<td>2710/22063</td>
<td>by chemical treatment</td>
</tr>
<tr>
<td>2710/22064</td>
<td>by serial passage</td>
</tr>
<tr>
<td>2710/22071</td>
<td>Demonstrated in vivo effect</td>
</tr>
<tr>
<td>2710/22088</td>
<td>For redistribution</td>
</tr>
<tr>
<td>2710/24011</td>
<td>Poxviridae</td>
</tr>
<tr>
<td>2710/24021</td>
<td>Viruses as such, e.g. new isolates, mutants or their genomic sequences</td>
</tr>
<tr>
<td>2710/24022</td>
<td>New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes</td>
</tr>
<tr>
<td>2710/24023</td>
<td>Virus like particles [VLP]</td>
</tr>
<tr>
<td>2710/24031</td>
<td>Uses of virus other than therapeutic or vaccine, e.g. disinfectant</td>
</tr>
<tr>
<td>2710/24032</td>
<td>Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent</td>
</tr>
<tr>
<td>2710/24033</td>
<td>Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory</td>
</tr>
<tr>
<td>2710/24034</td>
<td>Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein</td>
</tr>
<tr>
<td>2710/24041</td>
<td>Use of virus, viral particle or viral elements as a vector</td>
</tr>
<tr>
<td>2710/24042</td>
<td>virus or viral particle as vehicle, e.g. encapsulating small organic molecule</td>
</tr>
<tr>
<td>2710/24043</td>
<td>viral genome or elements thereof as genetic vector</td>
</tr>
<tr>
<td>2710/24044</td>
<td>Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2710/24045</td>
<td>Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2710/24051</td>
<td>Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2710/24052</td>
<td>relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2710/24061</td>
<td>Methods of inactivation or attenuation</td>
</tr>
<tr>
<td>2710/24062</td>
<td>by genetic engineering</td>
</tr>
<tr>
<td>2710/24063</td>
<td>by chemical treatment</td>
</tr>
<tr>
<td>2710/24064</td>
<td>by serial passage</td>
</tr>
<tr>
<td>2710/24071</td>
<td>Demonstrated in vivo effect</td>
</tr>
<tr>
<td>2710/24088</td>
<td>For redistribution</td>
</tr>
<tr>
<td>2710/24111</td>
<td>Orthopoxvirus, e.g. vaccinia virus, variola</td>
</tr>
<tr>
<td>2710/24121</td>
<td>Viruses as such, e.g. new isolates, mutants or their genomic sequences</td>
</tr>
<tr>
<td>2710/24122</td>
<td>New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes</td>
</tr>
<tr>
<td>2710/24123</td>
<td>Virus like particles [VLP]</td>
</tr>
<tr>
<td>2710/24131</td>
<td>Uses of virus other than therapeutic or vaccine, e.g. disinfectant</td>
</tr>
<tr>
<td>2710/24132</td>
<td>Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent</td>
</tr>
<tr>
<td>2710/24133</td>
<td>Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory</td>
</tr>
<tr>
<td>2710/24134</td>
<td>Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein</td>
</tr>
<tr>
<td>2710/24141</td>
<td>Use of virus, viral particle or viral elements as a vector</td>
</tr>
<tr>
<td>2710/24142</td>
<td>virus or viral particle as vehicle, e.g. encapsulating small organic molecule</td>
</tr>
<tr>
<td>2710/24143</td>
<td>viral genome or elements thereof as genetic vector</td>
</tr>
<tr>
<td>2710/24144</td>
<td>Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2710/24145</td>
<td>Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2710/24151</td>
<td>Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2710/24152</td>
<td>relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2710/24161</td>
<td>Methods of inactivation or attenuation</td>
</tr>
<tr>
<td>2710/24162</td>
<td>by genetic engineering</td>
</tr>
<tr>
<td>2710/24163</td>
<td>by chemical treatment</td>
</tr>
<tr>
<td>2710/24164</td>
<td>by serial passage</td>
</tr>
<tr>
<td>2710/24171</td>
<td>Demonstrated in vivo effect</td>
</tr>
<tr>
<td>2710/24188</td>
<td>For redistribution</td>
</tr>
<tr>
<td>2710/24211</td>
<td>Parapoxvirus, e.g. Orf virus</td>
</tr>
<tr>
<td>2710/24221</td>
<td>Viruses as such, e.g. new isolates, mutants or their genomic sequences</td>
</tr>
<tr>
<td>2710/24222</td>
<td>New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes</td>
</tr>
<tr>
<td>2710/24223</td>
<td>Virus like particles [VLP]</td>
</tr>
<tr>
<td>2710/24231</td>
<td>Uses of virus other than therapeutic or vaccine, e.g. disinfectant</td>
</tr>
<tr>
<td>2710/24232</td>
<td>Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent</td>
</tr>
<tr>
<td>2710/24233</td>
<td>Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory</td>
</tr>
<tr>
<td>2710/24234</td>
<td>Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein</td>
</tr>
<tr>
<td>2710/24241</td>
<td>Use of virus, viral particle or viral elements as a vector</td>
</tr>
<tr>
<td>2710/24242</td>
<td>virus or viral particle as vehicle, e.g. encapsulating small organic molecule</td>
</tr>
<tr>
<td>2710/24243</td>
<td>viral genome or elements thereof as genetic vector</td>
</tr>
<tr>
<td>2710/24244</td>
<td>Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2710/24245</td>
<td>Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2710/24251</td>
<td>Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2710/24252</td>
<td>relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2710/24261</td>
<td>Methods of inactivation or attenuation</td>
</tr>
<tr>
<td>2710/24262</td>
<td>by genetic engineering</td>
</tr>
<tr>
<td>2710/24263</td>
<td>by chemical treatment</td>
</tr>
<tr>
<td>2710/24264</td>
<td>by serial passage</td>
</tr>
<tr>
<td>2710/24271</td>
<td>Demonstrated in vivo effect</td>
</tr>
<tr>
<td>2710/24288</td>
<td>For redistribution</td>
</tr>
</tbody>
</table>

**dsRNA Viruses (not used)**

- 2720/00011: dsRNA Viruses
- 2720/00021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/00022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/00023: Virus like particles [VLP]
C12N 2720/00031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2720/00032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2720/00033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2720/00034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2720/00041 . . . Use of virus, viral particle or viral elements as a vector
2720/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2720/00043 . . . viral genome or elements thereof as genetic vector
2720/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/00045 . . . Special targeting system for viral vectors
2720/00051 . . . Methods of production or purification of viral material
2720/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2720/00061 . . . Methods of inactivation or attenuation
2720/00062 . . . by genetic engineering
2720/00063 . . . by chemical treatment
2720/00064 . . . by serial passage
2720/00071 . . . Demonstrated in vivo effect
2720/00088 . . . For redistribution
2720/10021 . . . Birnaviridae
2720/10022 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2720/10023 . . . Virus like particles [VLP]
2720/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2720/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2720/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2720/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2720/10041 . . . Use of virus, viral particle or viral elements as a vector
2720/10042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2720/10043 . . . viral genome or elements thereof as genetic vector
2720/10044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/10045 . . . Special targeting system for viral vectors
2720/10051 . . . Methods of production or purification of viral material
2720/10052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2720/10061 . . . Methods of inactivation or attenuation
2720/10062 . . . by genetic engineering
2720/10063 . . . by chemical treatment
2720/10064 . . . by serial passage
2720/10071 . . . Demonstrated in vivo effect
2720/10088 . . . For redistribution
2720/12011 . . . Reoviridae
2720/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2720/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2720/12023 . . . Virus like particles [VLP]
2720/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2720/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2720/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2720/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2720/12041 . . . Use of virus, viral particle or viral elements as a vector
2720/12042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2720/12043 . . . viral genome or elements thereof as genetic vector
2720/12044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/12045 . . . Special targeting system for viral vectors
2720/12051 . . . Methods of production or purification of viral material
2720/12052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2720/12061 . . . Methods of inactivation or attenuation
2720/12062 . . . by genetic engineering
2720/12063 . . . by chemical treatment
2720/12064 . . . by serial passage
2720/12071 . . . Demonstrated in vivo effect
2720/12088 . . . For redistribution
2720/12111 . . . Orbivirus, e.g. bluetongue virus
2720/12121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2720/12122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2720/12123 . . . Virus like particles [VLP]
2720/12131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2720/12132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2720/12133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2720/12134 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2720/12141 . . . Use of virus, viral particle or viral elements as a vector
2720/12142 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
Rotavirus, e.g. rotavirus A

Orthoreovirus, e.g. mammalian orthoreovirus

Uses of virus other than therapeutic or vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Methods of production or purification of viral material

For redistribution

Demonstrated in vivo effect

Reverse Transcribing DNA Viruses (not used)
Hepadnaviridae

Orthohepadnavirus, e.g. hepatitis B virus

For redistribution

Demonstrated in vivo effect

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

Methods of production or purification of viral material

related to complementing cells and packaging systems for producing virus or viral particles

relating to complementing cells and packaging systems for producing virus or viral particles

by serial passage

Reverse Transcribing RNA Viruses

For redistribution

Virus like particles [VLP]

Methods of production or purification of viral material

by serial passage

Methods of production or purification of viral material

by serial passage

Virus like particles [VLP]

by genetic engineering

Virus like particles [VLP]

by genetic engineering

Virus like particles [VLP]

Hepadnaviridae

Orthohepadnavirus, e.g. hepatitis B virus

For redistribution

Demonstrated in vivo effect

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

Methods of production or purification of viral material

related to complementing cells and packaging systems for producing virus or viral particles

relating to complementing cells and packaging systems for producing virus or viral particles

by serial passage

Reverse Transcribing RNA Viruses

For redistribution

Virus like particles [VLP]
Uses of virus other than therapeutic or vaccine, e.g. disinfectant
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Use of virus, viral particle or viral elements as a vector
Virus or viral particle as vehicle, e.g. encapsulating small organic molecule
Viral genome or elements thereof as genetic vector
Chimeric viral vector comprising heterologous viral elements for production of another viral vector
Special targeting system for viral vectors
Methods of production or purification of viral material
relating to complementing cells and packaging systems for producing virus or viral particles
Methods of inactivation or attenuation by genetic engineering
by chemical treatment
by serial passage
Demonstrated in vivo effect
For redistribution
Alpharetrovirus, e.g. avian leucosis virus
Viruses as such, e.g. new isolates, mutants or their genomic sequences
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Virus like particles [VLP]
Viral genome or elements thereof as genetic vector
Chimeric viral vector comprising heterologous viral elements for production of another viral vector
Special targeting system for viral vectors
Methods of production or purification of viral material
relating to complementing cells and packaging systems for producing virus or viral particles
Methods of inactivation or attenuation by genetic engineering
by chemical treatment
by serial passage
Demonstrated in vivo effect
For redistribution
Gammaretrovirus, e.g. murine leukeamia virus
Virus as therapeutic agent, other than vaccine, e.g. disinfectant
Virus or viral particle as vehicle, e.g. encapsulating small organic molecule
Viral genome or elements thereof as genetic vector
Chimeric viral vector comprising heterologous viral elements for production of another viral vector
Special targeting system for viral vectors
Methods of production or purification of viral material
relating to complementing cells and packaging systems for producing virus or viral particles
Methods of inactivation or attenuation by genetic engineering
by chemical treatment
by serial passage
Demonstrated in vivo effect
For redistribution
Betaretrovirus, e.g. mouse mammary tumour virus
Viruses as such, e.g. new isolates, mutants or their genomic sequences
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Virus like particles [VLP]
Uses of virus other than therapeutic or vaccine, e.g. disinfectant
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Use of virus, viral particle or viral elements as a vector
Virus or viral particle as vehicle, e.g. encapsulating small organic molecule
Viral genome or elements thereof as genetic vector
Chimeric viral vector comprising heterologous viral elements for production of another viral vector
Special targeting system for viral vectors
Methods of production or purification of viral material
relating to complementing cells and packaging systems for producing virus or viral particles
Methods of inactivation or attenuation by genetic engineering
by chemical treatment
by serial passage
Demonstrated in vivo effect
For redistribution
Betaretrovirus, e.g. mouse mammary tumour virus
Viruses as such, e.g. new isolates, mutants or their genomic sequences
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Virus like particles [VLP]
Uses of virus other than therapeutic or vaccine, e.g. disinfectant
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Use of virus, viral particle or viral elements as a vector
2740/13042 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/13043 . . . . . . viral genome or elements thereof as genetic vector
2740/13044 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/13045 . . . . . . Special targeting system for viral vectors
2740/13051 . . . . . . Methods of production or purification of viral material
2740/13052 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2740/13061 . . . . . . Methods of inactivation or attenuation
2740/13062 . . . . . . . by genetic engineering
2740/13063 . . . . . . . by chemical treatment
2740/13064 . . . . . . . by serial passage
2740/13071 . . . . . . Demonstrated in vivo effect
2740/13088 . . . . . . For redistribution
2740/14011 . . . . . . Deltaaretrovirus, e.g. bovine leukemia virus
2740/14021 . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/14022 . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/14023 . . . . . . Virus like particles [VLP]
2740/14031 . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/14032 . . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/14033 . . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/14034 . . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/14041 . . . . . . Use of virus, viral particle or viral elements as a vector
2740/14042 . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/14043 . . . . . . . viral genome or elements thereof as genetic vector
2740/14044 . . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/14045 . . . . . . Special targeting system for viral vectors
2740/14051 . . . . . . Methods of production or purification of viral material
2740/14052 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2740/14061 . . . . . . Methods of inactivation or attenuation
2740/14062 . . . . . . . by genetic engineering
2740/14063 . . . . . . . by chemical treatment
2740/14064 . . . . . . . by serial passage
2740/14071 . . . . . . Demonstrated in vivo effect
2740/14088 . . . . . . For redistribution
2740/15011 . . . . . . Lentivirus, not HIV, e.g. FIV, SIV
2740/15021 . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/15022 . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/15023 . . . . . . Virus like particles [VLP]
2740/15031 . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/15032 . . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/15033 . . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/15034 . . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/15041 . . . . . . Use of virus, viral particle or viral elements as a vector
2740/15042 . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/15043 . . . . . . . viral genome or elements thereof as genetic vector
2740/15044 . . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/15045 . . . . . . Special targeting system for viral vectors
2740/15051 . . . . . . Methods of production or purification of viral material
2740/15052 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2740/15061 . . . . . . Methods of inactivation or attenuation
2740/15062 . . . . . . . by genetic engineering
2740/15063 . . . . . . . by chemical treatment
2740/15064 . . . . . . . by serial passage
2740/15071 . . . . . . Demonstrated in vivo effect
2740/15088 . . . . . . For redistribution
2740/16011 . . . . . . Human Immunodeficiency Virus, HIV
2740/16021 . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/16022 . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/16023 . . . . . . Virus like particles [VLP]
2740/16031 . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/16032 . . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/16033 . . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/16034 . . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/16041 . . . . . . Use of virus, viral particle or viral elements as a vector
2740/16042 . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/16043 . . . . . . . viral genome or elements thereof as genetic vector
2740/16044 . . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/16045 . . . . . . Special targeting system for viral vectors
2740/16051 . . . . . . Methods of production or purification of viral material
2740/16052 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2740/16061 . . . . . . Methods of inactivation or attenuation
CPC - 2020.02

C12N

2740/16062 . . . . . by genetic engineering
2740/16063 . . . . . by chemical treatment
2740/16064 . . . . . by serial passage
2740/16071 . . . . . . Demonstrated in vivo effect
2740/16088 . . . . . For redistribution
2740/16111 . . . . . . concerning HIV env
2740/16122 . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/16134 . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/16171 . . . . . . Demonstrated in vivo effect
2740/16188 . . . . . For redistribution
2740/16211 . . . . . . concerning HIV gagpol
2740/16222 . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/16234 . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/16271 . . . . . . Demonstrated in vivo effect
2740/16288 . . . . . For redistribution
2740/16311 . . . . . . concerning HIV regulatory proteins
2740/16322 . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/16334 . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/16371 . . . . . . Demonstrated in vivo effect
2740/16388 . . . . . For redistribution
2740/17011 . . . . . . Spumavirus, e.g. chimpanzee foamy virus
2740/17021 . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/17022 . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/17023 . . . . . . Virus like particles [VLP]
2740/17031 . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/17032 . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/17033 . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/17034 . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/17041 . . . . . . Use of virus, viral particle or viral elements as a vector
2740/17042 . . . . . . Virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/17043 . . . . . . Viral genome or elements thereof as genetic vector
2740/17044 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/17045 . . . . . . Special targeting system for viral vectors
2740/17051 . . . . . . Methods of production or purification of viral material
2740/17052 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2740/17061 . . . . . . Methods of inactivation or attenuation
2740/17062 . . . . . . by genetic engineering
2740/17063 . . . . . . by chemical treatment
2740/17064 . . . . . . by serial passage
2740/17071 . . . . . . Demonstrated in vivo effect
2740/17088 . . . . . For redistribution

2750/00 ssDNA Viruses (not used)
2750/00011 . . . . ssDNA Viruses
2750/00021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2750/00022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2750/00023 . . . . Virus like particles [VLP]
2750/00031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2750/00032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2750/00033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2750/00034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2750/00041 . . . . Use of virus, viral particle or viral elements as a vector
2750/00042 . . . . Virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2750/00043 . . . . Viral genome or elements thereof as genetic vector
2750/00044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2750/00045 . . . . Special targeting system for viral vectors
2750/00051 . . . . Methods of production or purification of viral material
2750/00052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2750/00061 . . . . Methods of inactivation or attenuation
2750/00062 . . . . by genetic engineering
2750/00063 . . . . by chemical treatment
2750/00064 . . . . by serial passage
2750/00071 . . . . Demonstrated in vivo effect
2750/00088 . . . . For redistribution
2750/10011 . . . . Circoviridae
2750/10021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2750/10022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2750/10023 . . . . Virus like particles [VLP]
2750/10031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2750/10032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2750/10033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2750/10034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2750/10041 . . . . Use of virus, viral particle or viral elements as a vector

CPC - 2020.02 29
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2750/10042</td>
<td>. . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule</td>
</tr>
<tr>
<td>2750/10043</td>
<td>. . . viral genome or elements thereof as genetic vector</td>
</tr>
<tr>
<td>2750/10044</td>
<td>. . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2750/10045</td>
<td>. . . Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2750/10051</td>
<td>. . . Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2750/10052</td>
<td>. . . relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2750/10061</td>
<td>. . . Methods of inactivation or attenuation</td>
</tr>
<tr>
<td>2750/10062</td>
<td>. . . by genetic engineering</td>
</tr>
<tr>
<td>2750/10063</td>
<td>. . . by chemical treatment</td>
</tr>
<tr>
<td>2750/10064</td>
<td>. . . by serial passage</td>
</tr>
<tr>
<td>2750/10071</td>
<td>. . . Demonstrated in vivo effect</td>
</tr>
<tr>
<td>2750/10088</td>
<td>. . . For redistribution</td>
</tr>
<tr>
<td>2750/12011</td>
<td>. . . Geminiviridae</td>
</tr>
<tr>
<td>2750/12021</td>
<td>. . . Viruses as such, e.g. new isolates, mutants or their genomic sequences</td>
</tr>
<tr>
<td>2750/12022</td>
<td>. . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes</td>
</tr>
<tr>
<td>2750/12023</td>
<td>. . . Virus like particles [VLP]</td>
</tr>
<tr>
<td>2750/12031</td>
<td>. . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant</td>
</tr>
<tr>
<td>2750/12032</td>
<td>. . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent</td>
</tr>
<tr>
<td>2750/12033</td>
<td>. . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory</td>
</tr>
<tr>
<td>2750/12034</td>
<td>. . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein</td>
</tr>
<tr>
<td>2750/12041</td>
<td>. . . Use of virus, viral particle or viral elements as a vector</td>
</tr>
<tr>
<td>2750/12042</td>
<td>. . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule</td>
</tr>
<tr>
<td>2750/12043</td>
<td>. . . viral genome or elements thereof as genetic vector</td>
</tr>
<tr>
<td>2750/12044</td>
<td>. . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2750/12045</td>
<td>. . . Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2750/12051</td>
<td>. . . Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2750/12052</td>
<td>. . . relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2750/12061</td>
<td>. . . Methods of inactivation or attenuation</td>
</tr>
<tr>
<td>2750/12062</td>
<td>. . . by genetic engineering</td>
</tr>
<tr>
<td>2750/12063</td>
<td>. . . by chemical treatment</td>
</tr>
<tr>
<td>2750/12064</td>
<td>. . . by serial passage</td>
</tr>
<tr>
<td>2750/12071</td>
<td>. . . Demonstrated in vivo effect</td>
</tr>
<tr>
<td>2750/12088</td>
<td>. . . For redistribution</td>
</tr>
<tr>
<td>2750/14011</td>
<td>. . . Paroviridae</td>
</tr>
<tr>
<td>2750/14021</td>
<td>. . . Viruses as such, e.g. new isolates, mutants or their genomic sequences</td>
</tr>
<tr>
<td>2750/14022</td>
<td>. . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes</td>
</tr>
<tr>
<td>2750/14023</td>
<td>. . . Virus like particles [VLP]</td>
</tr>
<tr>
<td>2750/14031</td>
<td>. . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant</td>
</tr>
<tr>
<td>2750/14032</td>
<td>. . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent</td>
</tr>
<tr>
<td>2750/14033</td>
<td>. . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory</td>
</tr>
<tr>
<td>2750/14034</td>
<td>. . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein</td>
</tr>
<tr>
<td>2750/14041</td>
<td>. . . Use of virus, viral particle or viral elements as a vector</td>
</tr>
<tr>
<td>2750/14042</td>
<td>. . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule</td>
</tr>
<tr>
<td>2750/14043</td>
<td>. . . viral genome or elements thereof as genetic vector</td>
</tr>
<tr>
<td>2750/14044</td>
<td>. . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2750/14045</td>
<td>. . . Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2750/14051</td>
<td>. . . Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2750/14052</td>
<td>. . . relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2750/14061</td>
<td>. . . Methods of inactivation or attenuation</td>
</tr>
<tr>
<td>2750/14062</td>
<td>. . . by genetic engineering</td>
</tr>
<tr>
<td>2750/14063</td>
<td>. . . by chemical treatment</td>
</tr>
<tr>
<td>2750/14064</td>
<td>. . . by serial passage</td>
</tr>
<tr>
<td>2750/14071</td>
<td>. . . Demonstrated in vivo effect</td>
</tr>
<tr>
<td>2750/14088</td>
<td>. . . For redistribution</td>
</tr>
<tr>
<td>2750/14111</td>
<td>. . . Dependoviruses, e.g. adenoassociated viruses</td>
</tr>
<tr>
<td>2750/14121</td>
<td>. . . Viruses as such, e.g. new isolates, mutants or their genomic sequences</td>
</tr>
<tr>
<td>2750/14122</td>
<td>. . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes</td>
</tr>
<tr>
<td>2750/14123</td>
<td>. . . Virus like particles [VLP]</td>
</tr>
<tr>
<td>2750/14131</td>
<td>. . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant</td>
</tr>
<tr>
<td>2750/14132</td>
<td>. . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent</td>
</tr>
<tr>
<td>2750/14133</td>
<td>. . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory</td>
</tr>
<tr>
<td>2750/14134</td>
<td>. . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein</td>
</tr>
<tr>
<td>2750/14141</td>
<td>. . . Use of virus, viral particle or viral elements as a vector</td>
</tr>
<tr>
<td>2750/14142</td>
<td>. . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule</td>
</tr>
<tr>
<td>2750/14143</td>
<td>. . . viral genome or elements thereof as genetic vector</td>
</tr>
<tr>
<td>2750/14144</td>
<td>. . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector</td>
</tr>
<tr>
<td>2750/14145</td>
<td>. . . Special targeting system for viral vectors</td>
</tr>
<tr>
<td>2750/14151</td>
<td>. . . Methods of production or purification of viral material</td>
</tr>
<tr>
<td>2750/14152</td>
<td>. . . relating to complementing cells and packaging systems for producing virus or viral particles</td>
</tr>
<tr>
<td>2750/14161</td>
<td>. . . Methods of inactivation or attenuation</td>
</tr>
</tbody>
</table>
2750/14162 . . . . by genetic engineering
2750/14163 . . . . by chemical treatment
2750/14164 . . . . by serial passage
2750/14171 . . . . Demonstrated in vivo effect
2750/14188 . . . . For redistribution
2750/14211 . . . . Erythrovirus, e.g. B19 virus
2750/14221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2750/14222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2750/14223 . . . . Virus like particles [VLP]
2750/14231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2750/14232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2750/14233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2750/14234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2750/14241 . . . . Use of virus, viral particle or viral elements as a vector
2750/14242 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2750/14243 . . . . viral genome or elements thereof as genetic vector
2750/14244 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2750/14245 . . . . Special targeting system for viral vectors
2750/14251 . . . . Methods of production or purification of viral material
2750/14252 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2750/14261 . . . . Methods of inactivation or attenuation
2750/14262 . . . . by genetic engineering
2750/14263 . . . . by chemical treatment
2750/14264 . . . . by serial passage
2750/14271 . . . . Demonstrated in vivo effect
2750/14288 . . . . For redistribution
2750/14311 . . . . Parvovirus, e.g. minute virus of mice
2750/14321 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2750/14322 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2750/14323 . . . . Virus like particles [VLP]
2750/14331 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2750/14332 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2750/14333 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2750/14334 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2750/14341 . . . . Use of virus, viral particle or viral elements as a vector
2750/14342 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2750/14343 . . . . viral genome or elements thereof as genetic vector
2750/14344 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2750/14345 . . . . Special targeting system for viral vectors
2750/14351 . . . . Methods of production or purification of viral material
2750/14352 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2750/14361 . . . . Methods of inactivation or attenuation
2750/14362 . . . . by genetic engineering
2750/14363 . . . . by chemical treatment
2750/14364 . . . . by serial passage
2750/14371 . . . . Demonstrated in vivo effect
2750/14388 . . . . For redistribution
2760/00 ssRNA Viruses negative-sense (not used)
2760/00011 . . . . ssRNA Viruses negative-sense
2760/00021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/00022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/00023 . . . . Virus like particles [VLP]
2760/00031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/00032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/00033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/00034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/00041 . . . . Use of virus, viral particle or viral elements as a vector
2760/00042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/00043 . . . . viral genome or elements thereof as genetic vector
2760/00044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/00045 . . . . Special targeting system for viral vectors
2760/00051 . . . . Methods of production or purification of viral material
2760/00052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2760/00061 . . . . Methods of inactivation or attenuation
2760/00062 . . . . by genetic engineering
2760/00063 . . . . by chemical treatment
2760/00064 . . . . by serial passage
2760/00071 . . . . Demonstrated in vivo effect
2760/00088 . . . . For redistribution
2760/10021 . . . . Arenaviridae
Deltavirus, e.g. hepatitis delta virus

For redistribution

Methods of inactivation or attenuation

Methods of production or purification of viral material

Viral genome or elements thereof as genetic vector

Virus as such, e.g. new isolates, mutants or their genomic sequences

Virus like particles [VLP]

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Virus like particles [VLP]

Virus as such, e.g. new isolates, mutants or their genomic sequences

Virus like particles [VLP]

Virus like particles [VLP]
Filoviridae

- Uses of virus other than vaccine, e.g. as cytolytic agent
- Use of viral genome or elements thereof as genetic vector
- Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- Special targeting system for viral vectors
- Methods of production or purification of viral material
- relating to complementing cells and packaging systems for producing virus or viral particles
- Methods of inactivation or attenuation
- by serial passage
- Demonstrated in vivo effect
- For redistribution
- Ebolavirus, e.g. Zaire ebolavirus
- Demonstrated in vivo effect
- For redistribution
- Uses of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- Use of virus protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- Use of virus or viral component as vaccine, e.g. as cytolytic agent
- Use of virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- Viruses as such, e.g. new isolates, mutants or their genomic sequences
- New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Viruses like particles [VLP]
- Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Use of virus, viral particle or viral elements as a vector
- Methods of inactivation or attenuation
- by serial passage
- Demonstrated in vivo effect
- For redistribution
- Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- Special targeting system for viral vectors
- Methods of production or purification of viral material
- relating to complementing cells and packaging systems for producing virus or viral particles
- Methods of inactivation or attenuation
- by serial passage
- Demonstrated in vivo effect
- For redistribution
- Phlebovirus, e.g. Rift Valley fever virus
- Use of virus, viral particle or viral elements as a vector
- virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- viral genome or elements thereof as genetic vector
- Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- Special targeting system for viral vectors
- Methods of production or purification of viral material
- relating to complementing cells and packaging systems for producing virus or viral particles
- Methods of inactivation or attenuation
- by serial passage
- Demonstrated in vivo effect
- For redistribution
- New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Viruses like particles [VLP]
- Uses of virus other than therapeutic or vaccine, e.g. disinfectant
Use of virus, viral particle or viral elements as vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Orthomyxoviridae

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Influenzavirus B, i.e. influenza B virus

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Influenzavirus A, i.e. influenza A virus

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of viral protein as therapeutic agent other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Marburgvirus, e.g. lake Victoria marburgvirus

new viral protein or individual genes, new structural or functional aspects of a known viral protein or gene

uses of virus other than therapeutic or vaccine, e.g. disinfectant

use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

use of virus, viral particle or viral elements as a vector

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

demonstrated in vivo effect

methods of inactivation or attenuation

methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

demonstrated in vivo effect

for redistribution

influenzavirus A, i.e. influenza A virus

viruses as such, e.g. new isolates, mutants or their genomic sequences

new viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Influenzavirus B, i.e. influenza B virus

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of viral protein as therapeutic agent other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Influenzavirus B, i.e. influenza B virus

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Influenzavirus B, i.e. influenza B virus

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Influenzavirus B, i.e. influenza B virus

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Influenzavirus B, i.e. influenza B virus

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Influenzavirus B, i.e. influenza B virus

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Methods of inactivation or attenuation

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

Relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Influenzavirus C, i.e. influenza C virus

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses as such, e.g. live-attenuated or inactivated virus, VLP, viral protein

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Avulavirus, e.g. Newcastle disease virus

Methods of production or purification of viral material

Relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Special targeting system for viral vectors

Methods of production or purification of viral material

Relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Special targeting system for viral vectors

Methods of production or purification of viral material

Relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Special targeting system for viral vectors

Methods of production or purification of viral material

Relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by serial passage

Demonstrated in vivo effect

For redistribution

Paramyxoviridae

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of virus as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Use of virus, viral particle or viral elements as a vector

Use of virus, viral particle or viral elements as a vector

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of virus as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Use of virus, viral particle or viral elements as a vector

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

Relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by serial passage

Demonstrated in vivo effect

For redistribution

Avulavirus, e.g. Newcastle disease virus

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Avulavirus, e.g. Newcastle disease virus

Viruses as such, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of virus as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of virus as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of virus as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of virus as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of virus as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of virus as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of virus as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of virus as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of virus as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of virus as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector
Henipavirus, e.g. hendra virus

Vaccine, e.g. as cytolytic agent

Vaccine, e.g. disinfectant

Uses of virus other than therapeutic or anti-inflammatory

Viral proteins or genes

Structural or functional aspects of known virus or viral genome

For redistribution

Demonstrated in vivo effect

Methods of inactivation or attenuation

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

Methods of inactivation or attenuation

By serial passage

By genetic engineering

By chemical treatment

By genetic engineering

By chemical treatment

By serial passage

Demonstrated in vivo effect

For redistribution

Morbilivirus, e.g. Measles virus, canine distemper

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

Methods of inactivation or attenuation

By serial passage

By genetic engineering

By chemical treatment

By genetic engineering

By chemical treatment

By serial passage

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

methods of inactivation or attenuation

By serial passage

By genetic engineering

By chemical treatment

By serial passage

Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N

2760/18471 . . . . . . . Demonstrated in vivo effect
2760/18488 . . . . . . . For redistribution
2760/18511 . . . . . . . Pneumovirus, e.g. human respiratory syncytial virus
2760/18521 . . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/18522 . . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/18523 . . . . . . . Virus like particles [VLP]
2760/18531 . . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/18532 . . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/18533 . . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/18534 . . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/18541 . . . . . . . Use of virus, viral particle or viral elements as a vector
2760/18542 . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/18543 . . . . . . . viral genome or elements thereof as genetic vector
2760/18544 . . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/18545 . . . . . . . Special targeting system for viral vectors
2760/18551 . . . . . . . Methods of production or purification of viral material
2760/18552 . . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2760/18561 . . . . . . . Methods of inactivation or attenuation
2760/18562 . . . . . . . by genetic engineering
2760/18563 . . . . . . . by chemical treatment
2760/18564 . . . . . . . by serial passage
2760/18571 . . . . . . . Demonstrated in vivo effect
2760/18588 . . . . . . . For redistribution
2760/18611 . . . . . . . Respirovirus, e.g. Bovine, human parainfluenza 1,3
2760/18621 . . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/18622 . . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/18623 . . . . . . . Virus like particles [VLP]
2760/18631 . . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/18632 . . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/18633 . . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/18634 . . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/18641 . . . . . . . Use of virus, viral particle or viral elements as a vector
2760/18642 . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/18643 . . . . . . . viral genome or elements thereof as genetic vector
2760/18644 . . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/18645 . . . . . . . Special targeting system for viral vectors
2760/18651 . . . . . . . Methods of production or purification of viral material
2760/18652 . . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2760/18661 . . . . . . . Methods of inactivation or attenuation
2760/18662 . . . . . . . by genetic engineering
2760/18663 . . . . . . . by chemical treatment
2760/18664 . . . . . . . by serial passage
2760/18671 . . . . . . . Demonstrated in vivo effect
2760/18688 . . . . . . . For redistribution
2760/18711 . . . . . . . Rubulavirus, e.g. mumps virus, parainfluenza 2,4
2760/18721 . . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/18722 . . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/18723 . . . . . . . Virus like particles [VLP]
2760/18731 . . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/18732 . . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/18733 . . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/18734 . . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/18741 . . . . . . . Use of virus, viral particle or viral elements as a vector
2760/18742 . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/18743 . . . . . . . viral genome or elements thereof as genetic vector
2760/18744 . . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/18745 . . . . . . . Special targeting system for viral vectors
2760/18751 . . . . . . . Methods of production or purification of viral material
2760/18752 . . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2760/18761 . . . . . . . Methods of inactivation or attenuation
2760/18762 . . . . . . . by genetic engineering
2760/18763 . . . . . . . by chemical treatment
2760/18764 . . . . . . . by serial passage
2760/18771 . . . . . . . Demonstrated in vivo effect
2760/18788 . . . . . . . For redistribution
2760/18811 . . . . . . . Sendai virus
2760/18821 . . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/18822 . . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/18823 . . . . . . . Virus like particles [VLP]
2760/18831 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/18832 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/18833 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/18834 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/18841 . . . Use of virus, viral particle or viral elements as a vector
2760/18842 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/18843 . . . viral genome or elements thereof as genetic vector
2760/18845 . . . Special targeting system for viral vectors
2760/18851 . . . Methods of production or purification of viral material
2760/18852 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2760/18861 . . . Methods of inactivation or attenuation
2760/18862 . . . by genetic engineering
2760/18863 . . . by chemical treatment
2760/18864 . . . by serial passage
2760/18871 . . . Demonstrated in vivo effect
2760/18888 . . . For redistribution
2760/20011 . . . Rhabdoviridae
2760/20021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/20022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/20023 . . . Virus like particles [VLP]
2760/20031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/20032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/20033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/20034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/20041 . . . Use of virus, viral particle or viral elements as a vector
2760/20042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/20043 . . . viral genome or elements thereof as genetic vector
2760/20044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/20045 . . . Special targeting system for viral vectors
2760/20051 . . . Methods of production or purification of viral material
2760/20052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2760/20061 . . . Methods of inactivation or attenuation
2760/20062 . . . by genetic engineering
2760/20063 . . . by chemical treatment
2760/20064 . . . by serial passage
2760/20071 . . . Demonstrated in vivo effect
2760/20088 . . . For redistribution
2760/20111 . . . Lyssavirus, e.g. rabies virus
2760/20121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/20122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/20123 . . . Virus like particles [VLP]
2760/20131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/20132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/20133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/20134 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/20141 . . . Use of virus, viral particle or viral elements as a vector
2760/20142 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/20143 . . . viral genome or elements thereof as genetic vector
2760/20144 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/20145 . . . Special targeting system for viral vectors
2760/20151 . . . Methods of production or purification of viral material
2760/20152 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2760/20161 . . . Methods of inactivation or attenuation
2760/20162 . . . by genetic engineering
2760/20163 . . . by chemical treatment
2760/20164 . . . by serial passage
2760/20171 . . . Demonstrated in vivo effect
2760/20188 . . . For redistribution
2760/20211 . . . Vesiculovirus, e.g. vesicular stomatitis Indiana virus
2760/20221 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/20222 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/20223 . . . Virus like particles [VLP]
2760/20231 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/20232 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/20233 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/20234 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/20241 . . . Use of virus, viral particle or viral elements as a vector
2760/20242 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/20243 . . . viral genome or elements thereof as genetic vector
ssRNA Viruses positive-sense (not used)

2770/0011 . . . Viruses such as, e.g. new isolates, mutants or their genomic sequences
2770/0022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/0023 . . . Virus like particles [VLP]
2770/0031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/0032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/0033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/0034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/0041 . . . Use of virus, viral particle or viral elements as a vector
2770/0042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/0043 . . . viral genome or elements thereof as genetic vector
2770/0044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/0045 . . . Special targeting system for viral vectors
2770/0051 . . . Methods of production or purification of viral material
2770/0052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/0061 . . . Methods of inactivation or attenuation
2770/0062 . . . by genetic engineering
2770/0063 . . . by chemical treatment
2770/0064 . . . by serial passage
2770/0071 . . . Demonstrated in vivo effect
2770/0088 . . . For redistribution
2770/10011 . . . ssRNA Viruses positive-sense
2770/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/10041 . . . Use of virus, viral particle or viral elements as a vector
2770/10042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/10043 . . . viral genome or elements thereof as genetic vector
2770/10044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/10045 . . . Special targeting system for viral vectors
2770/10051 . . . Methods of production or purification of viral material
2770/10052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/10061 . . . Methods of inactivation or attenuation
2770/10062 . . . by genetic engineering
2770/10063 . . . by chemical treatment
2770/10064 . . . by serial passage
2770/10071 . . . Demonstrated in vivo effect
2770/10088 . . . For redistribution
2770/12011 . . . Astroviridae
2770/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/12023 . . . Virus like particles [VLP]
2770/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/12041 . . . Use of virus, viral particle or viral elements as a vector
2770/12042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/12043 . . . viral genome or elements thereof as genetic vector
2770/12044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/12045 . . . Special targeting system for viral vectors
2770/12051 . . . Methods of production or purification of viral material
2770/12052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/12061 . . . Methods of inactivation or attenuation
2770/12062 . . . by genetic engineering
2770/12063 . . . by chemical treatment
2770/20031 . . . . . . by serial passage
2770/20023 . . . . . . Methods of production or purification of viral material
2770/20022 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/20021 . . . . . . For redistribution
2770/20011 . . . . . . Caliciviridae
2770/18088 . . . . . . For redistribution
2770/18051 . . . . . . Methods of production or purification of viral material
2770/18052 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/18061 . . . . . . Methods of inactivation or attenuation
2770/18062 . . . . . . by genetic engineering
2770/18063 . . . . . . by chemical treatment
2770/18064 . . . . . . by serial passage
2770/18071 . . . . . . Demonstrated in vivo effect
2770/18088 . . . . . . For redistribution
2770/20011 . . . . . . Coronaviridae
2770/20021 . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/20022 . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/20023 . . . . . . by serial passage
2770/20064 . . . . . . by serial passage
2770/20065 . . . . . . by genetic engineering
2770/16064 . . . . . . by serial passage
2770/16065 . . . . . . by genetic engineering
2770/16045 . . . . . . Special targeting system for viral vectors
2770/16051 . . . . . . Methods of production or purification of viral material
2770/16052 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/16061 . . . . . . Methods of inactivation or attenuation
2770/16062 . . . . . . by genetic engineering
2770/16063 . . . . . . by chemical treatment
2770/16064 . . . . . . by serial passage
2770/16071 . . . . . . Demonstrated in vivo effect
2770/16088 . . . . . . For redistribution
2770/18023 . . . . . . Virus like particles [VLP]
2770/18031 . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/18032 . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/18033 . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/18034 . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/18041 . . . . . . Use of virus, viral particle or viral elements as a vector
2770/18042 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/18043 . . . . . . viral genome or elements thereof as genetic vector
2770/18044 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/18045 . . . . . . Special targeting system for viral vectors
2770/18051 . . . . . . Methods of production or purification of viral material
2770/18052 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/18061 . . . . . . Methods of inactivation or attenuation
2770/18062 . . . . . . by genetic engineering
2770/18063 . . . . . . by chemical treatment
2770/18064 . . . . . . by serial passage
2770/18071 . . . . . . Demonstrated in vivo effect
2770/18088 . . . . . . For redistribution
2770/20011 . . . . . . Coronaviridae
2770/20021 . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/20022 . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/20023 . . . . . . Virus like particles [VLP]
2770/20031 . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/20032 . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

CPC - 2020.02 40
2770/20033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/20034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/20041 . . . Use of virus, viral particle or viral elements as a vector
2770/20042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/20043 . . . viral genome or elements thereof as genetic vector
2770/20044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/20045 . . . Special targeting system for viral vectors
2770/20051 . . . Methods of production or purification of viral material
2770/20052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/20061 . . . Methods of inactivation or attenuation
2770/20062 . . . by genetic engineering
2770/20063 . . . by chemical treatment
2770/20064 . . . by serial passage
2770/20071 . . . Demonstrated in vivo effect
2770/20088 . . . For redistribution
2770/22011 . . . Dicistroviridae
2770/22021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/22022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/22023 . . . Virus like particles [VLP]
2770/22031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/22032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/22033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/22034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/22041 . . . Use of virus, viral particle or viral elements as a vector
2770/22042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/22043 . . . viral genome or elements thereof as genetic vector
2770/22044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/22045 . . . Special targeting system for viral vectors
2770/22051 . . . Methods of production or purification of viral material
2770/22052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/22061 . . . Methods of inactivation or attenuation
2770/22062 . . . by genetic engineering
2770/22063 . . . by chemical treatment
2770/22064 . . . by serial passage
2770/22071 . . . Demonstrated in vivo effect
Pestivirus, e.g. bovine viral diarrhea virus viral proteins or genes structural or functional aspects of known their genomic sequences Viruses as such, e.g. new isolates, mutants or for redistribution by serial passage by genetic engineering by chemical treatment by serial passage Demonstrated in vivo effect For redistribution Chimeric viral vector comprising heterologous viral elements for production of another viral vector Special targeting system for viral vectors Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles Methods of inactivation or attenuation by chemical treatment by genetic engineering by serial passage Demonstrated in vivo effect For redistribution Flexiviridae Viruses as such, e.g. new isolates, mutants or their genomic sequences New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes Virus like particles [VLP] Uses of virus other than therapeutic or vaccine, e.g. disinfectant Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule viral genome or elements thereof as genetic vector Chimeric viral vector comprising heterologous viral elements for production of another viral vector Special targeting system for viral vectors Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles Methods of inactivation or attenuation by genetic engineering by chemical treatment by serial passage Demonstrated in vivo effect For redistribution Virus like particles [VLP] Uses of virus other than therapeutic or vaccine, e.g. disinfectant Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule viral genome or elements thereof as genetic vector Chimeric viral vector comprising heterologous viral elements for production of another viral vector Special targeting system for viral vectors Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles Methods of inactivation or attenuation by genetic engineering by chemical treatment by serial passage Demonstrated in vivo effect For redistribution Pestivirus, e.g. bovine viral diarrhea virus Viruses as such, e.g. new isolates, mutants or their genomic sequences New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes Virus like particles [VLP] Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/26064 . . . . . by serial passage
2770/26071 . . . . . Demonstrated in vivo effect
2770/26088 . . . . . For redistribution
2770/28011 . . . . . Hepeviridae
2770/28021 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/28022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/28023 . . . . . Virus like particles [VLP]
2770/28031 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/28032 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/28033 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/28034 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/28041 . . . . . Use of virus, viral particle or viral elements as a vector
2770/28042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/28043 . . . . . viral genome or elements thereof as genetic vector
2770/28044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/28045 . . . . . Special targeting system for viral vectors
2770/28051 . . . . . Methods of production or purification of viral material
2770/28052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/28061 . . . . . Methods of inactivation or attenuation
2770/28062 . . . . . by genetic engineering
2770/28063 . . . . . by chemical treatment
2770/28064 . . . . . by serial passage
2770/28071 . . . . . Demonstrated in vivo effect
2770/28088 . . . . . For redistribution
2770/28111 . . . . . Hepeivirus, e.g. hepatitis E virus
2770/28121 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/28122 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/28123 . . . . . Virus like particles [VLP]
2770/28131 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/28132 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/28133 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/28134 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/28141 . . . . . Use of virus, viral particle or viral elements as a vector
2770/28142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/28143 . . . . . viral genome or elements thereof as genetic vector
2770/28144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/28145 . . . . . Special targeting system for viral vectors
2770/28151 . . . . . Methods of production or purification of viral material
2770/28152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/28161 . . . . . Methods of inactivation or attenuation
2770/28162 . . . . . by genetic engineering
2770/28163 . . . . . by chemical treatment
2770/28164 . . . . . by serial passage
2770/28171 . . . . . Demonstrated in vivo effect
2770/28188 . . . . . For redistribution
2770/30011 . . . . . Nodaviridae
2770/30021 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/30022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/30023 . . . . . Virus like particles [VLP]
2770/30031 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/30032 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/30033 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/30034 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/30041 . . . . . Use of virus, viral particle or viral elements as a vector
2770/30042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/30043 . . . . . viral genome or elements thereof as genetic vector
2770/30044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/30045 . . . . . Special targeting system for viral vectors
2770/30051 . . . . . Methods of production or purification of viral material
2770/30052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/30061 . . . . . Methods of inactivation or attenuation
2770/30062 . . . . . by genetic engineering
2770/30063 . . . . . by chemical treatment
2770/30064 . . . . . by serial passage
2770/30071 . . . . . Demonstrated in vivo effect
2770/30088 . . . . . For redistribution
2770/32011 . . . . . Picornaviridae
2770/32021 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/32022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/32023 . . . . . Virus like particles [VLP]
2770/32031 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/32032 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

For redistribution

Demonstrated in vivo effect

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

virus or viral particle as vehicle, e.g. encapsulating small organic molecule

viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles
Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Methods of inactivation or attenuation

Virus like particles [VLP]

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Methods of production or purification of viral material

Special targeting system for viral vectors

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

For redistribution

Structural or functional aspects of known viral proteins or genes

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Usual methods of inactivation or attenuation

Virus like particles [VLP]

Use of virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

For redistribution

Virus like particles [VLP]

Use of virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

For redistribution

Virus like particles [VLP]

Use of virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Chimeric viral vector comprising heterologous viral elements for production of another viral vector
Parechovirus, e.g. human parechovirus

Use of virus as therapeutic agent, other than vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Virus like particles [VLP]

Methods of inactivation or attenuation

by serial passage

Methods of production or purification of viral material

Virus like particles [VLP]

Methods of inactivation or attenuation

by chemical treatment

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Methods of inactivation or attenuation

by genetic engineering

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Methods of inactivation or attenuation

by genetic engineering

Viruses as such, e.g. new isolates, mutants or their genomic sequences

Use of virus, viral particle or viral elements as a vector

Methods of inactivation or attenuation

by serial passage

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Methods of inactivation or attenuation

by genetic engineering

Use of virus, viral particle or viral elements as a vector

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Methods of inactivation or attenuation

by genetic engineering
2770/32688 . . . . For redistribution
2770/32711 . . . . Rhinovirus
2770/32721 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/32722 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/32723 . . . . Virus like particles [VLP]
2770/32731 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/32732 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/32733 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/32734 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/32741 . . . . Use of virus, viral particle or viral elements as a vector
2770/32742 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/32743 . . . . viral genome or elements thereof as genetic vector
2770/32744 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/32745 . . . . Special targeting system for viral vectors
2770/32751 . . . . Methods of production or purification of viral material
2770/32752 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/32761 . . . . Methods of inactivation or attenuation
2770/32762 . . . . by genetic engineering
2770/32763 . . . . by chemical treatment
2770/32764 . . . . by serial passage
2770/32771 . . . . Demonstrated in vivo effect
2770/32788 . . . . For redistribution
2770/34011 . . . . Potyviridae
2770/34021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/34022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/34023 . . . . Virus like particles [VLP]
2770/34031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/34032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/34033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/34034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/34041 . . . . Use of virus, viral particle or viral elements as a vector
2770/34042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/34043 . . . . viral genome or elements thereof as genetic vector
2770/34044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/34045 . . . . Special targeting system for viral vectors
2770/34051 . . . . Methods of production or purification of viral material
2770/34052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/34061 . . . . Methods of inactivation or attenuation
2770/34062 . . . . by genetic engineering
2770/34063 . . . . by chemical treatment
2770/34064 . . . . by serial passage
2770/34071 . . . . Demonstrated in vivo effect
2770/34088 . . . . For redistribution
2770/36011 . . . . Togaviridae
2770/36021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/36022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/36023 . . . . Virus like particles [VLP]
2770/36031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/36032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/36033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/36034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/36041 . . . . Use of virus, viral particle or viral elements as a vector
2770/36042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/36043 . . . . viral genome or elements thereof as genetic vector
2770/36044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/36045 . . . . Special targeting system for viral vectors
2770/36051 . . . . Methods of production or purification of viral material
2770/36052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2770/36061 . . . . Methods of inactivation or attenuation
2770/36062 . . . . by genetic engineering
2770/36063 . . . . by chemical treatment
2770/36064 . . . . by serial passage
2770/36071 . . . . Demonstrated in vivo effect
2770/36088 . . . . For redistribution
2770/36111 . . . . Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
2770/36121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/36122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/36123 . . . . Virus like particles [VLP]
2770/36131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
Methods of inactivation or attenuation

Use of virus, viral particle or viral elements as a vector

- virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- viral genome or elements thereof as genetic vector
- Chimeric viral vector comprising heterologous viral elements for production of another viral vector

- Special targeting system for viral vectors

- Methods of production or purification of viral material

- relating to complementing cells and packaging systems for producing virus or viral particles

- Methods of inactivation or attenuation

- by genetic engineering
- by chemical treatment
- by serial passage
- Demonstrated in vivo effect

- For redistribution

- Rubivirus, e.g. rubella virus

- Viruses as such, e.g. new isolates, mutants or their genomic sequences

- New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

- Virus like particles [VLP]

- Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

- Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

- by serial passage

- Demonstrated in vivo effect

- For redistribution

- New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

- Virus like particles [VLP]

- Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

- Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

- by chemical treatment
**Naked RNA Viruses (not used)**

- 2780/00011: Naked RNA Viruses
- 2780/00021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2780/00022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2780/00023: Virus like particles [VLP]
- 2780/00031: Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2780/00032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2780/00033: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2780/00034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2780/00041: Use of virus, viral particle or viral elements as a vector
- 2780/00042: Virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2780/00043: Viral genome or elements thereof as genetic vector
- 2780/00044: Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2780/00045: Special targeting system for viral vectors
- 2780/00051: Methods of production or purification of viral material
- 2780/00052: relating to complementing cells and packaging systems for producing virus or viral particles
- 2780/00061: Methods of inactivation or attenuation
- 2780/00062: by genetic engineering
- 2780/00063: by chemical treatment
- 2780/00064: by serial passage
- 2780/00071: Demonstrated in vivo effect
- 2780/00088: For redistribution

**Viroids and subviral agents (not used)**

- 2790/00011: Viroids and subviral agents
- 2790/00021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/00022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/00023: Virus like particles [VLP]
- 2790/00031: Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/00032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/00033: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/00034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/00041: Use of virus, viral particle or viral elements as a vector
- 2790/00042: Virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/00043: Viral genome or elements thereof as genetic vector
- 2790/00044: Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/00045: Special targeting system for viral vectors
- 2790/00051: Methods of production or purification of viral material
- 2790/00052: relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/00061: Methods of inactivation or attenuation
- 2790/00062: by genetic engineering
- 2790/00063: by chemical treatment
- 2790/00064: by serial passage
- 2790/00071: Demonstrated in vivo effect
- 2790/00088: For redistribution
Prions

Virus like particles [VLP]

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Virus as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Virus as such, e.g. new isolates, mutants or their genomic sequences

Virus as such, e.g. new isolates, mutants or their genomic sequences

Virus like particles [VLP]

Virus like particles [VLP]

Virus as such, e.g. new isolates, mutants or their genomic sequences

Virus like particles [VLP]

Virus like particles [VLP]
2792/00031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2792/00032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2792/00033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2792/00034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2792/00041 . . . Use of virus, viral particle or viral elements as a vector
2792/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2792/00043 . . . viral genome or elements thereof as genetic vector
2792/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2792/00045 . . . Special targeting system for viral vectors
2792/00051 . . . Methods of production or purification of viral material
2792/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2792/00061 . . . Methods of inactivation or attenuation
2792/00062 . . . by genetic engineering
2792/00063 . . . by chemical treatment
2792/00064 . . . by serial passage
2792/00071 . . . Demonstrated in vivo effect
2792/00088 . . . For redistribution
2792/10011 . . . Fuselloviridae
2792/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2792/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2792/10023 . . . Virus like particles [VLP]
2792/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2792/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2792/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2792/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2792/10041 . . . Use of virus, viral particle or viral elements as a vector
2792/10042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2792/10043 . . . viral genome or elements thereof as genetic vector
2792/10044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2792/10045 . . . Special targeting system for viral vectors
2792/10051 . . . Methods of production or purification of viral material
2792/10052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2792/10061 . . . Methods of inactivation or attenuation
2792/10062 . . . by genetic engineering

2792/10063 . . . by chemical treatment
2792/10064 . . . by serial passage
2792/10071 . . . Demonstrated in vivo effect
2792/10088 . . . For redistribution
2792/12011 . . . Guttaviridae
2792/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2792/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2792/12023 . . . Virus like particles [VLP]
2792/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2792/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2792/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2792/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2792/12041 . . . Use of virus, viral particle or viral elements as a vector
2792/12042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2792/12043 . . . viral genome or elements thereof as genetic vector
2792/12044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2792/12045 . . . Special targeting system for viral vectors
2792/12051 . . . Methods of production or purification of viral material
2792/12052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
2792/12061 . . . Methods of inactivation or attenuation
2792/12062 . . . by genetic engineering
2792/12063 . . . by chemical treatment
2792/12064 . . . by serial passage
2792/12071 . . . Demonstrated in vivo effect
2792/12088 . . . For redistribution

2795/00 Bacteriophages (not used)
2795/00011 . . . Bacteriophages
2795/00021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2795/00022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2795/00023 . . . Virus like particles [VLP]
2795/00031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2795/00032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2795/00033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2795/00034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2795/00041 . . . Use of virus, viral particle or viral elements as a vector
dsDNA Bacteriophages

Methods of inactivation or attenuation of viral material
Methods of production or purification of viral material
Methods of inactivation or attenuation relating to complementing cells and packaging systems for producing virus or viral particles

Myoviridae

Methods of inactivation or attenuation
by genetic engineering
by chemical treatment
by serial passage

Demonstrated \textit{in vivo} effect

For redistribution
dsDNA Bacteriophages

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Virus like particles [VLP]

Use of virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material
Methods of inactivation or attenuation relating to complementing cells and packaging systems for producing virus or viral particles

Virus like particles [VLP]

Viral genome or elements thereof as genetic vector

Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Special targeting system for viral vectors

Methods of production or purification of viral material
Methods of inactivation or attenuation relating to complementing cells and packaging systems for producing virus or viral particles

Virus like particles [VLP]
C12N

2795/10262 . . . . . . by genetic engineering
2795/10263 . . . . . . by chemical treatment
2795/10264 . . . . . . by serial passage
2795/10271 . . . . . . Demonstrated in vivo effect
2795/10288 . . . . . . For redistribution
2795/10311 . . . . . . Siphoviridae
2795/10321 . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2795/10322 . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2795/10323 . . . . . . Virus like particles [VLP]
2795/10331 . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2795/10332 . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2795/10333 . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2795/10334 . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2795/10341 . . . . . . Use of virus, viral particle or viral elements as a vector
2795/10342 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2795/10343 . . . . . . viral genome or elements thereof as genetic vector
2795/10344 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2795/10345 . . . . . . Special targeting system for viral vectors
2795/10351 . . . . . . Methods of production or purification of viral material
2795/10352 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2795/10361 . . . . . . Methods of inactivation or attenuation
2795/10362 . . . . . . by genetic engineering
2795/10363 . . . . . . by chemical treatment
2795/10364 . . . . . . by serial passage
2795/10371 . . . . . . Demonstrated in vivo effect
2795/10388 . . . . . . For redistribution
2795/12011 . . . . . . ssDNA Bacteriophages
2795/12021 . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2795/12022 . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2795/12023 . . . . . . Virus like particles [VLP]
2795/12031 . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2795/12032 . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2795/12033 . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2795/12034 . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2795/12041 . . . . . . Use of virus, viral particle or viral elements as a vector
2795/12042 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2795/12043 . . . . . . viral genome or elements thereof as genetic vector
2795/12044 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2795/12045 . . . . . . Special targeting system for viral vectors
2795/12051 . . . . . . Methods of production or purification of viral material
2795/12052 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2795/12061 . . . . . . Methods of inactivation or attenuation
2795/12062 . . . . . . by genetic engineering
2795/12063 . . . . . . by chemical treatment
2795/12064 . . . . . . by serial passage
2795/12071 . . . . . . Demonstrated in vivo effect
2795/12088 . . . . . . For redistribution
2795/14011 . . . . . . dsDNA Bacteriophages
2795/14021 . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2795/14022 . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2795/14023 . . . . . . Virus like particles [VLP]
2795/14031 . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2795/14032 . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2795/14033 . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2795/14034 . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2795/14041 . . . . . . Use of virus, viral particle or viral elements as a vector
2795/14042 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2795/14043 . . . . . . viral genome or elements thereof as genetic vector
2795/14044 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2795/14045 . . . . . . Special targeting system for viral vectors
2795/14051 . . . . . . Methods of production or purification of viral material
2795/14052 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
2795/14061 . . . . . . Methods of inactivation or attenuation
2795/14062 . . . . . . by genetic engineering
2795/14063 . . . . . . by chemical treatment
2795/14064 . . . . . . by serial passage
2795/14071 . . . . . . Demonstrated in vivo effect
2795/14088 . . . . . . For redistribution
2795/14111 . . . . . . Inoviridae
2795/14121 . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2795/14122 . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2795/14123 . . . . . . Virus like particles [VLP]
2795/14131 . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Use of virus, viral particle or viral elements as a vector

Methods of inactivation or attenuation of viral material

Methods of production or purification of viral material

relating to complementing cells and packaging systems for producing virus or viral particles

Methods of inactivation or attenuation

by genetic engineering

by chemical treatment

by serial passage

Demonstrated in vivo effect

For redistribution

Microviridae

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Virus like particles [VLP]

Microviridae

Viruses as such, e.g. new isolates, mutants or their genomic sequences

New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Viruses like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Virus like particles [VLP]

Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Virus like particles [VLP]
Uses of viruses

**WARNING**

From March 15, 2012 codes in the range C12N 2799/00 - C12N 2799/06 are no longer used for the classification of new documents. The documents in this range are being reclassified to the corresponding codes in C12N 2710/00 - C12N 2795/00.

2799/02  as vector
<table>
<thead>
<tr>
<th>CPC</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2810/75</td>
<td>. . from invertebrates</td>
</tr>
<tr>
<td>2810/80</td>
<td>. . from vertebrates</td>
</tr>
<tr>
<td>2810/85</td>
<td>. mammalian</td>
</tr>
<tr>
<td>2810/851</td>
<td>. . . from growth factors; from growth regulators</td>
</tr>
<tr>
<td>2810/852</td>
<td>. . . from cytokines; from lymphokines; from interferons</td>
</tr>
<tr>
<td>2810/853</td>
<td>. . . from tumor necrosis factor, TNF</td>
</tr>
<tr>
<td>2810/854</td>
<td>. . . from hormones</td>
</tr>
<tr>
<td>2810/855</td>
<td>. . . from receptors; from cell surface antigens; from cell surface determinants</td>
</tr>
<tr>
<td>2810/856</td>
<td>. . . from integrins</td>
</tr>
<tr>
<td>2810/857</td>
<td>. . . from blood coagulation or fibrinolysis factors</td>
</tr>
<tr>
<td>2810/858</td>
<td>. . . from apolipoproteins</td>
</tr>
<tr>
<td>2810/859</td>
<td>. . . from immunoglobulins</td>
</tr>
<tr>
<td>2810/90</td>
<td>. avian</td>
</tr>
</tbody>
</table>

### 2820/00 Vectors comprising a special origin of replication system

- 2820/002 . inducible or controllable
- 2820/005 . cell-cycle regulated
- 2820/007 . tissue or cell-specific
- 2820/10  . multiple origins of replication
- 2820/55  . from bacteria
- 2820/60  . from viruses
- 2820/65  . from plants
- 2820/70  . from fungi
- 2820/702 . yeast
- 2820/704 . S. cerevisiae
- 2820/706 . S. pombe
- 2820/708 . C. albicans
- 2820/75  . from invertebrates
- 2820/80  . from vertebrates
- 2820/85  . mammalian
- 2820/90  . avian

### 2830/00 Vector systems having a special element relevant for transcription

- 2830/001 . controllable enhancer/promoter combination
- 2830/002 . inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- 2830/003 . tet inducible
- 2830/005 . repressible enhancer/promoter combination, e.g. KRAB
- 2830/006 . tet repressible
- 2830/007 . cell cycle specific enhancer/promoter combination
- 2830/008 . cell type or tissue specific enhancer/promoter combination
- 2830/15  . chimeric enhancer/promoter combination
- 2830/20  . transcription of more than one cistron
- 2830/205 . bidirectional
- 2830/30  . being an enhancer not forming part of the promoter region
- 2830/32  . being a silencer not forming part of the promoter region
- 2830/34  . being a transcription initiation element
- 2830/36  . being a transcription termination element
- 2830/38  . being a stuffer
- 2830/40  . being an insulator
- 2830/42  . being an intron or intervening sequence for splicing and/or stability of RNA
- 2830/46  . elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island

### 2840/00 Vectors comprising a special translation-regulating system

- 2840/002 . controllable or inducible
- 2840/005 . cell cycle specific
- 2840/007 . cell or tissue specific
- 2840/10  . regulates levels of translation
- 2840/102 . inhibiting translation
- 2840/105 . enhancing translation
- 2840/107 . inhibiting translational read-through
- 2840/20  . translation of more than one cistron
- 2840/203 . having an IRES
- 2840/206 . having multiple IRES
- 2840/44  . being a specific part of the splice mechanism, e.g. donor, acceptor
- 2840/445 . for trans-splicing, e.g. polypyrimidine tract, branch point splicing
- 2840/50  . utilisation of non-ATG initiation codon

#### NOTE
This groups covers artificial modification only, i.e. naturally occurring use of non-ATG start codon is not classified here

- 2840/55  . from bacteria
- 2840/60  . from viruses
- 2840/65  . from plants
- 2840/70  . from fungi
- 2840/702 . yeast
- 2840/704 . S. cerevisiae
- 2840/706 . S. pombe
- 2840/708 . C. albicans
- 2840/75  . from invertebrates
- 2840/80  . from vertebrates
- 2840/85  . mammalian
- 2840/90  . avian

### 2999/00 Further aspects of viruses or vectors not covered by the C12N 2700/00 or C12N 2800/00 series

#### NOTES
1. This group is for classification of patent and non-patent literature documents.
2. When classifying non-patent literature in this group, classification must also be given for the relevant CPC groups, to define the technical area to which they relate.
2999/002. Adverse teaching

2999/005. Biological teaching, e.g. a link between protein and disease, new virus causing pandemic

2999/007. Technological advancements, e.g. new system for producing known virus, cre-lox system for production of transgenic animals